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1CHAPTER 1: INTRODUCTION
The ultimate goal of any biological experiment is to understand the underlying phe-
nomenon of the condition investigated. Technologies such as microarray [102], and RNA-
seq [151] make it possible to capture the expression level of thousands of genes at the same
time. Understanding how genes interact with each other is the key to understand how the
cell works and as a result, how diseases evolve. At the same time, this knowledge can be
used to design better drugs and improve the standard of medical care. Previously, single-gene
statistical analyses were used to identify the genes that are responsible for a given condi-
tion. This type of analysis is not able to provide a complete understanding of the disease.
By understanding how genes interact, we can first construct networks that describe specific
mechanisms and later combine them at a system level to provide a global perspective.
A very important step in system biology, is the identification of the networks that are
most impacted in the given condition. These networks, called gene regulatory networks or
pathways, are modeled as graphs where the nodes represent genes and the edges represent
the interactions between them. Such networks explain where the target genes are affected
by some other genes, and therefore describe the mechanisms involved in a biological process.
Genes that have similar behavior (e.g., have high correlation) in different conditions
are considered to be involved in similar cellular functions. These genes may share a tran-
scription factor. We need to answer the question of which genes cause the impact in a specific
condition and how they interact [52].
The networks that explain the interactions between genes can be used to: 1) predict
the disease or the responses of the system to a specific impact, 2) find the subset of genes
that interact with each other and play an important role in the condition of interest, and 3)
understand the mechanisms involved in that condition [7, 29, 83].
We are addressing above mentioned problem by introducing two main strategies.
First, we are taking advantage of pre-defined pathways obtained from existing databases to
identify the impact of a phenotype studied on such pathways.
2Figure 2.1: KEGG apoptosis signaling pathway (from: http://www.genome.jp/kegg/
pathway/hsa/hsa04210.html).
A pathway describes all the known phenomena involved in a given biological process,
to which it is associated. It is part of a larger system that has a set of components interacting
with each other. These components work together to achieve a common goal. The name of a
pathway usually represents the biological process, phenomenon, or disease process described
by the pathway. Different types of interactions are described by different types of edges, or
weights in the structure of a pathway. As an example, Figure 2.1 shows the apoptosis sig-
naling pathway, which includes the genes and interactions involved in the known mechanism
for cell death. Different types of interactions are shown by different arrows.
In this research, we are introducing a pathway analysis method that compares two
phenotypes and helps identifying the pathways that are significantly impacted between the
two phenotypes. The ranks of the pathways represent the significance of their perturbation
in one phenotype versus another. Correctly identifying the pathways that are impacted in a
disease condition is a crucial step in understanding that disease. This method aims to reduce
3the false positives and false negatives in the existing methods by focusing on the primary
dis-regulation of the gene itself in comparison with the effects coming from upstream genes.
A common avenue pursued in order to understand the differences between phenotypes
involves the selection of a subset of “differentially expressed” (DE) genes. Usually, the tens
of thousands of measured genes are reduced to a small set of a few hundred DE genes,
essentially discarding about 99% of the measurements. Our hypothesis is that the drastic
filtering necessary in order to select this subset of DE genes could discard many genes that
play important roles in the given phenotype. The pathway analysis method proposed here
takes full advantage of the current technologies and uses the measured data for the entire set
of 30,000-100,000 transcripts in the genome, thus allowing the full use of the data provided by
current techniques. The proposed method is validated on 24 datasets involving 12 different
human disease, as well as 8 yeast knock-out datasets. It yields significant improvements with
respect to the state-of-the-art methods.
Second, we are proposing a method that identifies a subset of genes and interactions
relevant to the given phenotype. The identified subset known as the active network includes
the genes that are strongly involved in the phenotype studied. One of the drawbacks of the
existing curated pathways or gene interactions databases is that each interaction is extracted
from literature or experimentally validated by independent studies. However, most such
interactions were found in specific tissues and/or phenotype, and not all studies employed the
same tissue and/or phenotype. Therefore, these independently identified interactions in the
databases may not exist in the actual phenotype or tissue studied in a subsequent experiment.
Furthermore, new phenomena may be involved in the tissue or phenotype currently being
studied. Utilizing only existing pathways from pathways databases or literature, limits one’s
ability to discover new phenomena and new interactions.
In order to overcome such limitations, some existing methods try to build the regula-
tory networks based on the correlation or the co-expression existing in the given datasets [55,
71, 107, 157]. The networks resulting from such methods are specific to the condition under
4study, but the interactions identified are only based on the genes’ expression level. This
limitation can produce many false positives as well as false negatives, because an interaction
between two genes is not necessarily reflected in the correlation between their expression
levels. The interactions between genes can involve an indirect relation between them via
their protein products or their transcription factors, and sometimes interactions take place
on different time scales. Therefore, there is a need for computational algorithms able to
construct network of active interactions by analyzing data in more sophisticated ways, by
combining gene expression data with existing pathway information, as well as with data from
protein-protein interactions databases. Such methods identify the network of interactions
that is most relevant to a given phenotype based on the retrieved prior knowledge, referred
to as “active network”. This network is also known as “network hotspot” or “responsive
subnetwork” [86].
The active network, as part of a global interaction network, explains the sudden
changes in the genes activity or the characteristic of the phenotype in a given disease. This
network is identified based on the given data and can be considered as the putative mech-
anism involved in the given phenotype. The advantage of identifying an active network is
that it is specific to the condition studied, as opposed to existing curated pathways that can
describe more generic knowledge, not necessarily applicable to the given condition.
In this manuscript, we propose a method that uses interactions obtained from differ-
ent databases to infer the active networks. Also, we propose two validation approaches to
evaluate the results. First approach is computing a pathway enrichment score to assess the
significance of the overlaps between identified network and known pathways. The second
approach is computing the percentage of the genes in the identified network that are known
to be relevant to the condition based on an existing database. We validated the method
on multiple datasets from experiments studying colorectal cancer, renal cancer and prostate
cancer. We compare our result with the results of two widely used methods: NetWalker and
HotNet, and the classical approach of considering just the union of differentially expressed
5(DE). The results of these comparisons show that the proposed method yields improvements
in constructing networks, which are significantly relevant to the given diseases based on the
resulting genes and interactions.
6CHAPTER 2: PRIMARY DIS-REGULATION
2.1 Background
The goal of pathway analysis methods is to identify the most perturbed pathways in a
given condition. Pathways are divided in two main categories: i) signaling pathways, that are
defined as graphs in which nodes represent genes/proteins and edges are interactions between
them, and ii) metabolic pathways in which the nodes represent biochemical compounds and
the edges represent reactions, carried out by enzymes which are coded by genes [87]. Such
pathways describe all known phenomena involved in a biological process (e.g. cell cycle),
or a disease (e.g. Alzheimer’s disease), etc. In this thesis, we focus on signaling pathways
to be able to map the measured expression level of the genes to the corresponding nodes
in those pathways. Intuitively, the impact of a given phenotype on a given pathway should
be determined by the number of differentially expressed (DE) genes on that pathway, the
magnitude of the changes in the expression level of the genes, and the type, direction and
strength of the interactions between the genes in that pathway.
The simplest pathway analysis approach is the over-representation analysis (ORA) [62].
This approach considers only the number of DE genes that are present in a given pathway.
ORA techniques calculate the probability of finding a certain number of DE genes among
all the genes in a pathway just by chance. Another approach to pathway analysis is the
functional class scoring (FCS) [63, 87]. This approach takes into consideration all measured
expression changes, as well as the correlation between the expression change of the genes and
the phenotype. The most popular techniques in the FCS category are Gene Set Enrichment
Analysis (GSEA) [121] and Gene Set Analysis (GSA) [35]. These two techniques rank the
genes based on the correlation between their expression and a given phenotype, and calculate
a score that reflects the degree to which a given pathway is represented at extremes of the
ranked list. Neither of these two approaches considers the interactions between genes, their
direction, type, strength, etc. In essence, all these methods treat the pathways as simple
sets of genes.
7However, databases such as KEGG [93], BioCarta [16] and Reactome [56] provide
pathways that consist of much more than just sets of genes. These databases provide complex
graphs for each signaling pathways in which each node is a gene/protein and each edge is an
interaction between two such genes or proteins. Ignoring the wealth of knowledge captured
in the topology of the pathway is clearly sub-optimal. Even though these databases provide
more detailed information about the topology of the pathways, there are thousands of genes
that have not been annotated yet. Furthermore, many of the existing annotations may be
inaccurate [63]. However, we believe that accuracy and reliability of pathways annotation
is growing and using this type of information can only help the interpretation of high-
throughput experiments.
More recently, more sophisticated methods have been proposed that are able to fully
take into consideration all the interactions between genes in signaling pathways to find which
pathway is most impacted by a given phenotype [32]. These are sometimes referred to as
“topology-aware” or “third generation” pathway analysis methods [63, 87]. The method,
proposed in this manuscript, belongs to this latest generation of pathway analysis methods,
inasmuch it considers the topology of the pathways, as well as the changes in expression level
of the genes.
However, even the most sophisticated current pathway analysis methods still produce
both false positives as well as false negatives in certain circumstances. We hypothesized
that such incorrect results are due to the fact that the existing methods fail to distinguish
between the primary dis-regulation of a given gene itself and the effects of signals coming
from upstream. We hypothesize that better results could be achieved if one distinguishes
between genes that are true sources of perturbation, e.g. due to mutations, copy number
variations, epigenetic changes, etc. and genes that merely respond to perturbation signals
coming from upstream. Intuitively, a pathway should be more significantly impacted if it
hosts more genes that are such true sources of perturbation. The method proposed here is
8an attempt at capturing these differences by calculating a “primary dis-regulation” for every
gene and using them to compute a total pathway perturbation and subsequent significance.
Another issue related to the traditional topological data analysis approaches involves
the need for a selection of differentially expressed (DE) genes. Traditionally, the pathway
analysis step is performed after a set of DE genes has been selected using some thresholds
on some criteria such as fold-change and/or p-values. Typically, a set of a few hundred
genes are selected as DE. However, a modern whole-genome experiment performed with a
next-generation technology (NGS) provides measurements for the entire set of transcripts
in the genome, albeit for a non-trivial cost in computation necessary for the assembly and
quantification of millions of short reads. In addition to the high computational cost, other
drawbacks are related to the large amount of storage space, and the need to specialized
bioinformatics expertise to set-up and run the environment necessary for the analysis. Given
that this great deal of effort is spent in order to measure over 30,000 transcripts, it makes
little sense to discard approximately 99% of these measurements in order to focus on 300
or so genes that are declared to be differentially expressed. Subsequently, the pathway
analysis step aims to identify system-level changes based on only these 1% of the original
data collected. More recently, approaches that are able to identify significantly impacted
pathways based on the entire set of measurements have been proposed [144]. Henceforth,
we will refer to the original approach based on DE genes as the cut-off -based approach, and
to the threshold-free approach as the all genes approach. We assessed the novel method
proposed here with both types of input.
In the following section, we describe our new proposed method in details. We eval-
uate the preliminary results of our method using 24 datasets involving 12 conditions from
different experiments comparing disease versus normal tissues. The results of the proposed
method using the cut-off -based approach are compared with SPIA (cut-off) [127], which
also uses a pre-selected list of DE genes as input. The results of the proposed method using
the all genes approach are compared with GSEA [121], GSA [35] and SPIA (all genes) [144]
9which use entire set of genes as input. These existing methods have been selected as refer-
ences in our comparisons because they are among the most cited and widely used methods
in the literature [87]. We also evaluate our method using eight yeast knock-out datasets
from different experiments comparing samples with knock-out gene versus normal samples.
The comparisons show that the proposed method is able to perform better than the most
widely used pathway analysis methods, in identifying the relevant pathways as statistically
significant.
2.2 Primary dis-regulation analysis
The measured expression change of a gene in a given phenotype can be seen as the
result of influences from upstream genes superposed on the dis-regulation incurred by that
particular gene itself. We will refer to this later quantity as the primary dis-regulation (pDis).
The diffusion of signals between genes in regulatory networks, called “network propagation”,
can be used to find the active genes and subnetworks as well as the function of the genes in
different conditions [53]. Widely used methods in this field are introduced in [149] and [141].
Here, we are using a similar approach that uses propagation between genes to calculate pDis
in order to find the most impacted pathways. We propose a pathway analysis method that
focuses on this primary dis-regulation.
The change in the expression level of a gene i, ∆E(gi), can be seen as a sum of the
primary dis-regulation (pDis) and the secondary dis-regulation (sDis):
∆E(gi) = pDis(gi) + sDis(gi) (2.1)
The secondary dis-regulation of the gene gi is the term that is meant to capture the
perturbation reaching this particular gene from upstream. This can be calculated by adding
the expression change of upstream genes normalized by the number of their downstream
10
Figure 2.1: An example of one upstream gene and its three downstream genes. pDis(gi) is
calculated using its measured fold change of ∆E(gi) and measured fold change of upstream
genes (e.g. ∆E(gj)). In this example, the number of downstream genes for gj is Nds(gj) = 3.
genes:
∆E(gi) = pDis(gi) +
∑
j∈U
βi,j ·∆E(gj)
Nds(gj)
(2.2)
In the equation above, ∆E(gj) is the measured fold change of the gene gj that is
somewhere directly upstream of gi, U is the set of all such genes directly upstream of gi, and
Nds(gj) is the number of genes immediately downstream of gj (see Figure 2.1). The quantity
βi,j represents efficiency of the interaction between genei and genej. It captures a specific
value if an interaction is available between two genes. We used +1 if the interaction type is
activation or expression and −1 if it is inhibition or repression as default values. This is the
same approach used by the impact analysis [32].
The primary dis-regulation, which gives the change in a gene expression inherent to
the gene itself, can then be derived as follows:
pDis(gi) = ∆E(gi)−
∑
j∈U
βi,j ·∆E(gj)
Nds(gj)
(2.3)
The primary dis-regulation is meant to capture information about the genes that are
sources of perturbation in a given phenotype, rather than those genes that change as a result
of upstream changes. For instance, a mutation that induce expression changes would be
captured by the gene’s primary dis-regulation, while expression changes due to upstream
11
Figure 2.2: A small fragment of a pathway, which includes PSEN1. The gene PSEN1 has
4 downstream genes. There are two types of interactions in this example: the arrows show
activation, while the terminal bars show inhibition. The colors represent the expression
changes of the genes (blue is down-regulation).
signaling would be captured by the secondary dis-regulation. A mutation is an example
that is sufficient but not necessary to create primary dis-regulation. Other potential cause
could be copy number variations, epigenetic changes such as methylation, etc. The intuition
motivating the computation of the primary dis-regulation is that pathways that have more
genes that are sources of perturbation are more likely to be truly involved in the phenotype.
This computation can be illustrated on the small example shown in Figure 2.2. This
figure shows a subgraph from the KEGG Alzheimer’s disease pathway. The colors represent
the log transformed expression change of those genes in the experiment (darker blue rep-
resents more down-regulation). The value of β between genes PSEN1 and RYR3 has been
assigned +1 because PSEN1 activates RYR3; the values of betas between PSEN1 and there
other 3 genes are -1 because PSEN1 inhibits those downstream genes.
We can see in this figure that gene PSEN1 is down-regulated and it interacts with
four downstream genes (one activation and three inhibitions). Among the four downstream
genes, RYR3, EIF2A and ERN1 are not differentially expressed, thus their measured ∆Es
are zero. The effect of the gene PSEN1 on each downstream gene is equal to its expression
change divided by the number of its downstream genes, which in this case is four. Since
RYR3, EIF2A, ERN1 and ATF6 have only PSEN1 as an upstream gene, we calculate their
pDis based on equation 2.3 as follows:
pDis(RY R3) = ∆E(RY R3)−∆E(PSEN1)/4 (2.4)
12
pDis(EIF2A) = ∆E(EIF2A) + ∆E(PSEN1)/4 (2.5)
pDis(ERN1) = ∆E(ERN1) + ∆E(PSEN1)/4 (2.6)
pDis(ATF6) = ∆E(ATF6) + ∆E(PSEN1)/4 (2.7)
The process of calculating all values of the primary dis-regulation for all the genes in
a given pathway can be summarized using the matrix equation:
pDis = ∆ET · (I −B) (2.8)
In this equation, the matrix B represents the adjacency matrix of each signaling pathway
normalized by the number of downstream genes of each gene.
B =

β1,1/Nds(g1) β1,2/Nds(g2) ... β1,n/Nds(gn)
β2,1/Nds(g1) β2,2/Nds(g2) ... β2,n/Nds(gn)
... ... ... ...
βn,1/Nds(g1) βn,2/Nds(g2) ... βn,n/Nds(gn)

In equation 2.8, I is an identity matrix with dimensions equal to the number of genes
in a pathway, and ∆E is the vector of measured expression changes of the genes in that
13
pathway:
∆E =

∆E(g1)
∆E(g2)
...
∆E(gn)

The score for pathway k is calculated as the sum of the absolute values of primary dis-
regulation of all the genes in the pathway, totalpDis:
totalpDisk =
∑
i∈pathwayk
|pDis(gi)| (2.9)
The quantity totalpDis of a pathway represents the amount of primary dis-regulation
of the whole pathway in the condition under study.
The significance of each pathway is assessed by computing the probability of obtaining
just by chance a totalpDis value more extreme than the one observed. This probability is
estimated using a bootstrap approach where the null distribution for totalpDis for each
pathway is generated by sampling random gene expression changes from the original set of
expression changes. The number of bootstraps used was 2,000. This process is repeated for
all pathways and yields a p-value for each pathway. Subsequently, the set of p-values for all
pathways are corrected for multiple comparisons using the false discovery rate (FDR). The
average running time for a dataset is 6.3 minutes on an architecture using a single Intel Xeon
core @ 2.66GHz with 1TB of RAM. The complexity of the method depends on the number
of pathways investigated multiply by the number of genes in each pathways (O(N2)).
2.3 Cut-off dependent versus cut-off free analysis
Pathway analysis techniques often take a subset of statistically significant genes as
input, based on cut-offs for expression change and/or p-value. It has been shown in [95]
that small variations of the threshold used to select the subset of differentially expressed
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(DE) genes has dramatic effects on the outcome of the methods. Hence, the accuracy of any
pathway analysis methods using a subset of DE genes will also be very dependent on the
threshold(s) used. Furthermore, when using a cut-off, some genes that play an important
biological role may fail to meet the selection criteria and thus, not included in the set of
DE genes. This can potentially impede the identification of the biologically meaningful
pathways.
Recently, it has also been shown that the accuracy of a pathway analysis method can
be improved by using the entire set of measurement from an experiment rather than a subset
of DE genes [144]. This means that a selection of a set of DE genes may no longer be needed
in many situations.
With respect to the method proposed in this research, the use of a subset of DE
genes will affect the values of the pDis of other genes in a pathway. The pDis of a gene is
simply equal to the expression change when there are no upstream DE genes. However, when
such upstream genes do exist, pDis is calculated using the expression changes of upstream
genes as well. The inclusion of all genes in the calculation will have a strong impact on the
result, even if the expression changes are small. This allows the analysis to retain all of the
information in the data, avoiding arbitrary threshold choices.
We refer to this method as pDis analysis (all genes), as opposed to pDis analysis
(cut-off) for cut-off based. We show the results from both types of input sets applied to our
new method proposed.
2.4 Discussion and results
To date there is no universally accepted technique for the validation of the results
of pathway analysis methods. The assessment of the results of different pathway analysis
methods usually involves the selection of a few datasets, and then the interpretation of the
results either with the help of biologists in the field, or by searching the published literature.
This approach is very limited because it can only be applied to a small number of datasets.
Furthermore, it is subjective, and may lead to bias in the results since most of the time the
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expert who performs the assessment is also a co-author of the paper. Finally, the biological
phenomena are so complex that with enough literature search, a large number of pathways
can be implicated in almost any condition. In this work, we follow two validation approaches.
The first one is the validation approach introduced in [126]. We like this evaluation approach
because it is objective, reproducible, based on multiple datasets, and it does not require an
unavoidably biased “expert” human evaluation of the results [126]. This approach requires
testing on a large number (at least 10 but preferably more) of different datasets coming
from a variety of different conditions, tissues, and laboratories. The datasets are selected
such that there are specific pathways in the pathway databases that model each of the given
diseases. For each dataset, the pathway corresponding to the phenotype is considered to
be the target pathway (e.g. the colorectal cancer pathway will be the target pathway in a
colorectal cancer dataset). The evaluation focuses on the ability of each method to identify
these true positive pathways as significant, and rank them as high as possible. In this thesis,
we validated the proposed method using 24 datasets involving 12 different human diseases.
These datasets are shown in Table 2.1.
The second approach uses knock-out datasets. In this case, the exact source of per-
turbation is known: the specific gene being knock-out. Thus the pathways that include
this gene will be truly relevant to the phenotype, since they contain the very source of the
perturbation that created the phenotype. In other words, these pathways are true positives
and are also considered as the target pathways in our validation.
The p-values (representing the probability of observing the given perturbations just
by chance) are used to assign significance to each pathway. The list of pathways is then
ranked based on these p-values.
In order to formalize and quantify the assessment, we define an “improvement factor”
that will be used to compare the performance of two pathway analysis methods. If the target
pathway for a given dataset goes from not significant in the results of method 1 to significant
in the results of method 2, the improvement factor for this dataset will be 1 (see Figure 2.3).
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GEO ID Pubmed Reference Disease Target Pathway
1 GSE1297 14769913 [17] Alzheimer’s Disease hsa05010
2 GSE5281 17077275 [74] Alzheimer’s Disease hsa05010
3 GSE5281 17077275 [74] Alzheimer’s Disease hsa05010
4 GSE5281 17077275 [74] Alzheimer’s Disease hsa05010
5 GSE20153 20926834 [156] Parkinson’s disease hsa05012
6 GSE20291 15965975 [155] Parkinson’s disease hsa05012
7 GSE8762 17724341 [110] Huntington’s disease hsa05016
8 GSE4107 17317818 [50] Colorectal Cancer hsa05210
9 GSE8671 18171984 [111] Colorectal Cancer hsa05210
10 GSE9348 20143136 [49] Colorectal Cancer hsa05210
11 GSE14762 19252501 [150] Renal Cancer hsa05211
12 GSE781 14641932 [73] Renal Cancer hsa05211
13 GSE15471 19260470 [2] Pancreatic Cancer hsa05212
14 GSE16515 19732725 [97] Pancreatic Cancer hsa05212
15 GSE19728 NA NA Glioma hsa05214
16 GSE21354 NA NA Glioma hsa05214
17 GSE6956 18245496 [147] Prostate Cancer hsa05215
18 GSE6956 18245496 [147] Prostate Cancer hsa05215
19 GSE3467 16365291 [45] Thyroid Cancer hsa05216
20 GSE3678 NA NA Thyroid Cancer hsa05216
21 GSE9476 17910043 [120] Acute myeloid leukemia hsa05221
22 GSE18842 20878980 [112] Non-Small Cell Lung Cancer hsa05223
23 GSE19188 20421987 [51] Non-Small Cell Lung Cancer hsa05223
24 GSE3585 17045896 [11] Dilated cardiomyopathy hsa05414
Table 2.1: The twenty-four datasets from the GEO database used to evaluate the pathway
analysis methods compared in this thesis. Each dataset corresponds to a disease for which
there is a target pathway in KEGG.
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Figure 2.3: The improvement factor criterion used to assess the results. Alpha (α) rep-
resents the chosen significance threshold. The green and red arrows denote situations in
which method 2 is better or worse than method 1, respectively. The number on each ar-
row represents the value the improvement factor in each case. If a target pathway becomes
significant in the results of method 2, the improvement factor for that target pathway will
be +1 (e.g. target pathway TP1); if the pathway becomes not significant, the improvement
factor is considered -1 (e.g. TP4). If the target remains on the same side of the significance
threshold, the improvement factor is considered +0.5 or -0.5 based on the improvement or
deterioration of the rank, respectively (e.g. TP2 and TP3).
If the target pathway goes from significant to not significant, the improvement factor will be
-1. If the significance of the target pathway does not change but the ranking improves, the
improvement factor will be +0.5. Finally, if the significance does not change but the ranking
worsens, the improvement will be -0.5. If the ranking remains the same, the improvement is
zero for that dataset. The improvement of method 2 compared to method 1 is the average of
improvement factors associated to each target pathway over the set of 24 different datasets.
If the overall improvement is positive, then method 2 is considered to perform better than
method 1 based on this validation method.
The proposed method is implemented using the R statistical programming environ-
ment [129] and is available as a Bioconductor R package (ROntoTools [145]). We used KEGG
signaling pathways as input pathways. The pathways were obtained from the “SPIA” R pack-
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age version 2.14.0 [128] as included in Bioconductor version 2.13, released on October 15,
2013. We selected all pathways that have at least one interaction with the type of activa-
tion, inhibition, repression or expression between their genes. This resulted in a set of 139
pathways. The results of pDis analysis (all genes) are compared to GSA, GSEA and SPIA
(all genes) and the results of pDis analysis (cut-off) are compared to SPIA (cut-off). SPIA
(cut-off) combines two different p-values. One is the perturbation p-value (pPERT) of a
pathway. The perturbation p-value is computed based on the perturbation accumulation of
the pathway, which is the sum of the perturbation factors of its genes. The other p-value
of SPIA is the hypergeometric p-value, based on the number of DE genes in the pathway
in a given dataset. Since the number of DE genes in each pathway does not depend on the
analysis method, the hypergeometric p-value is the same in SPIA (cut-off) and the method
proposed.
Each dataset was normalized by the “mar” normalization method available in the
“affy” R package (version 1.38.1) [54] from Bioconductor version 2.12, released on April 4,
2013. For each gene, the probe id was mapped to gene Entrez ID. The fold change between
normal and disease conditions for each probe was calculated by using the “limma” package
(version 3.16.8) [118] from Bioconductor version 2.12, released on April 4, 2013. We used the
log2-transform of the fold changes for each gene in our analysis. The moderated t-test was
performed on each probe to compute the significance of the changes between two phenotypes.
For the methods that use cut-off approach, we used a 5% threshold to select the DE genes.
2.4.1 Results of the target pathways for 24 disease datasets
The ranks and p-values of target pathways in all human disease datasets are shown in
Figure. 2.4. The details of the results for the proposed and reference methods are provided in
Table 2.3 (SPIA and pDis analysis (cut-off) and Table 2.4, 2.5 and 2.6 (GSEA, GSA, SPIA
(all genes) and pDis analysis (all genes)). The distributions of the ranks and the p-values
obtained for the target pathways in four methods are shown as boxplots in Figure. 2.4.
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P-value (paired t-test p-
value)
SPIA (cut-off) GSA GSEA SPIA (all genes)
pDis analysis (cut-off) 0.01 - - -
pDis analysis (all genes) - 0.07 0.074 0.01
Ranks (paired
Wilcoxon.test p-value)
SPIA (cut-off) GSA GSEA SPIA (all genes)
pDis analysis (cut-off) 0.13 - - -
pDis analysis (all genes) - 0.75 0.29 0.05
Table 2.2: Results of the statistical tests that were performed to compare the results of the
various pathway analysis methods. pDis analysis (cut-off) was compared to SPIA (cut-off).
pDis analysis (all genes) was compared to GSEA, GSA and SPIA (all genes). Each p-value
shows whether the ranks and the p-values of the target pathways in proposed method are
significantly lower than the reference methods (at 5% significance threshold). The results
show that pDis analysis (cut-off) yields significantly better p-values than SPIA (cut-off) for
the target pathways. Also, pDis analysis (all genes) yields lower p-values as well as lower
ranks compared to GSEA and SPIA (all genes).
The paired t-test and the paired Wilcoxon test were performed to compare the dis-
tribution of the ranks and p-values of target pathways in each method. The results are
shown in Table 2.2. The statistical tests are performed as one-tail tests in order to test
whether the ranks and p-values of target pathways in proposed methods are significantly
lower than the reference methods. The results show that the p-values of the target pathways
in pDis analysis (cut-off) are significantly lower than SPIA. Furthermore, the ranks and the
p-values of the target pathways in pDis analysis (all genes) is significantly lower than GSEA.
The p-values of pDis analysis (all genes) are also lower than those yielded by GSA but not
significantly so (at 5%).
The pDis analysis (all genes) yields better results compared to GSEA, in term of
both ranks (panel C in Figure 2.4, Wilcoxon test p-value = 0.29), as well as p-values of the
target pathways (panel D in Figure 2.4, t-test p-value = 0.074). The proposed method yields
significantly better results compared to SPIA (all genes) in terms of both ranks (panel C in
Figure 2.4, Wilcoxon test p-value = 0.05), as well as p-values of the target pathways (panel D
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GEO ID Target pathway SPIA (pPERT) pDis analysis (cut-off) Improvement
p-values FDR ranks p-values FDR ranks Compared to
SPIA
1 GSE1297 Alzheimer’s Disease 0.916 1.00 78.79 0.729 0.987 70.83 +0.5
2 GSE5281 Alzheimer’s Disease 0.807 1.00 71.53 0.022 0.328 6.20 +0.5
3 GSE5281 Alzheimer’s Disease 0.956 1.00 92.54 0.006 0.201 2.99 +0.5
4 GSE5281 Alzheimer’s Disease 0.831 0.985 82.20 0.068 0.359 18.94 +0.5
5 GSE20153 Parkinson’s disease 1 1.00 62.82 1 1.00 98.72 -0.5
6 GSE20291 Parkinson’s disease 0.129 0.712 18.10 0.425 0.803 50.48 -0.5
7 GSE8762 Huntington’s disease 1 1.00 69.49 0.425 0.524 79.66 -0.5
8 GSE4107 Colorectal Cancer 0.011 0.213 5.15 0.023 0.184 12.50 -0.5
9 GSE8671 Colorectal Cancer 0.406 0.778 50.74 0.351 0.772 44.12 +0.5
10 GSE9348 Colorectal Cancer 0.198 0.503 37.96 0.387 0.679 56.93 -0.5
11 GSE14762 Renal Cancer 0.009 0.07 12.04 0.482 0.786 61.31 -0.5
12 GSE781 Renal Cancer 0.412 1.00 36.94 0.859 0.935 91.79 -0.5
13 GSE15471 Pancreatic Cancer 0.651 0.843 76.47 0.451 0.757 59.56 +0.5
14 GSE16515 Pancreatic Cancer 0.94 1.00 88.15 0.452 0.796 55.56 +0.5
15 GSE19728 Glioma 0.979 1.00 91.24 0.235 0.485 47.45 +0.5
16 GSE21354 Glioma 0.367 0.744 49.26 0.342 0.560 61.03 -0.5
17 GSE6956 Prostate Cancer 0.21 1.00 17.28 0.771 0.981 74.26 -0.5
18 GSE6956 Prostate Cancer 0.592 1.00 54.13 0.555 0.993 41.32 +0.5
19 GSE3467 Thyroid Cancer 0.745 0.957 77.78 0.57 0.925 58.52 +0.5
20 GSE3678 Thyroid Cancer 0.59 0.987 59.70 0.313 0.706 41.04 +0.5
21 GSE9476 Acute myeloid leukemia 0.164 0.841 18.11 0.064 0.825 5.51 +0.5
22 GSE18842 Non-Small Cell Lung Can-
cer
0.395 0.857 44.53 0.06 0.348 16.79 +0.5
23 GSE19188 Non-Small Cell Lung Can-
cer
0.97 1.00 93.43 0.176 0.560 31.39 +0.5
24 GSE3585 Dilated cardiomyopathy 1 1.00 81.18 0.577 0.825 69.89 +0.5
Average 0.595 0.854 57.06 0.389 0.682 48.19 +3/24=12.5%
Table 2.3: The ranks and the p-values of the 24 target pathways for SPIA (cut-off) and
pDis analysis (cut-off). The improvement factor based on Figure 2.3 is calculated for each
dataset considering the 5% significance threshold using FDR-corrected p-values. The average
improvement factor shows that pDis analysis (cut-off) improves 12.5% compared to SPIA
(cut-off). As shown, the average p-value and rank for the target pathways are lower (i.e.
better) in pDis analysis (cut-off) than in SPIA (cut-off).
in Figure 2.4, t-test p-value =0.01). The results also show that the proposed method provides
more significant p-values compared to GSA, even thought the differences are not statistically
significant (see Table 2.2). There is not significant difference between the ranks yielded by
pDis (all genes) and GSA. The figure also shows the comparison between pDis analysis (cut-
off) and SPIA (cut-off). The proposed method yields significantly better results compared
to SPIA (cut-off) in terms of p-values (panel B in Figure 2.4, t-test p=0.01). The results
are also better in terms of ranks, even though the difference is not statistically significant
(panel A in Fig 2.4, Wilcoxon test p-value =0.13).
As some diseases are complex phenotypes involving fundamental biochemical path-
ways, other pathways might be significantly impacted in addition to the target pathway.
Therefore, we studied the detailed results of pDis analysis (all genes) on a dataset, in order
to show that our method is not limited to identifying the target pathway as significantly im-
pacted, but it is also able to correctly report relevant fundamental biochemical mechanisms
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Figure 2.4: The ranks (in the left column, lower is better) and negative log of p-values of
the target pathways (in the right column, higher is better) in the proposed and reference
methods. The first row (panel A and panel B) shows the comparison between methods using
a set of DE genes: pDis (cut-off) and SPIA (cut-off). The second row (panel C and panel D)
shows the comparison between methods using all genes: GSEA, GSA and SPIA (all genes),
pDis (all genes). For SPIA, the comparisons are based on the perturbation p-value (pPERT).
All human signaling pathways from KEGG (139 pathways) were used in the comparisons.
The data show the results obtained for the target pathways in the 24 datasets shown in
Table 2.1. The bold line in the boxplots represents the median of the distribution. These
distributions show that the proposed method pDis analysis (in blue) is never significantly
worse than any of the existing methods, while it yields a statistically significant improvement
in 5 out of the 8 comparisons (see Table 2.2).
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GEO ID Target pathway GSA pDis analysis (all genes) Improvement
p-values FDR ranks p-values FDR ranks Compared to
GSA
1 GSE1297 Alzheimer’s Disease 0.100 0.514 19.42 5e-06 5.7e-05 4.74 +1.0
2 GSE5281 Alzheimer’s Disease 0.316 0.872 33.09 5e-06 3.6e-05 7.29 +1.0
3 GSE5281 Alzheimer’s Disease 0.116 0.488 23.74 5e-06 2.6e-05 9.85 +1.0
4 GSE5281 Alzheimer’s Disease 0.164 0.537 27.69 5e-06 2.6e-05 9.85 +1.0
5 GSE20153 Parkinson’s disease 0.542 0.885 54.67 0.002 0.008 21.53 +1.0
6 GSE20291 Parkinson’s disease 0.246 0.629 35.61 5e-06 2.2e-05 11.67 +1.0
7 GSE8762 Huntington’s disease 0.154 0.876 15.10 5e-06 1.6e-05 15.32 +1.0
8 GSE4107 Colorectal Cancer 0.154 0.764 20.14 0.002 0.009 20.43 +1.0
9 GSE8671 Colorectal Cancer 0.002 0.069 2.87 0.116 0.248 46.71 -0.5
10 GSE9348 Colorectal Cancer 0.032 0.342 9.35 0.054 0.172 31.02 -0.5
11 GSE14762 Renal Cancer 0.132 0.600 21.58 0.029 0.062 46.71 -0.5
12 GSE781 Renal Cancer 0.492 0.865 56.47 0.998 0.998 100 -0.5
13 GSE15471 Pancreatic Cancer 0.112 0.622 17.98 0.168 0.247 67.88 -0.5
14 GSE16515 Pancreatic Cancer 0.062 0.625 8.63 0.121 0.242 49.63 -0.5
15 GSE19728 Glioma 0.136 0.548 24.46 5e-06 2.2e-05 11.31 +1.0
16 GSE21354 Glioma 0.128 0.547 22.66 5e-06 2.1e-05 12.04 +1.0
17 GSE6956 Prostate Cancer 0.060 0.440 9.35 0.031 0.124 24.45 -0.5
18 GSE6956 Prostate Cancer 0.032 0.451 6.47 0.001 0.013 6.56 +1.0
19 GSE3467 Thyroid Cancer 0.152 0.687 20.14 0.018 0.061 28.83 -0.5
20 GSE3678 Thyroid Cancer 0.464 0.814 56.11 0.201 0.364 54.38 +0.5
21 GSE9476 Acute myeloid leukemia 0.128 0.902 10.07 5e-06 9.7e-05 2.92 +1.0
22 GSE18842 Non-Small Cell Lung Can-
cer
0.156 0.6992 20.86 0.496 0.635 78.10 -0.5
23 GSE19188 Non-Small Cell Lung Can-
cer
0.446 0.844 48.92 0.874 0.925 93.43 -0.5
24 GSE3585 Dilated cardiomyopathy 0.866 0.919 91.36 0.093 0.364 25.54 +0.5
Average 0.216 0.647 27.368 0.133 0.186 32.51 +8/24=33.3%
Table 2.4: The ranks and the p-values of the 24 target pathways for GSA and pDis analysis
(all genes). The improvement factor based on Figure 2.3 is calculated for each dataset con-
sidering 5% significance threshold using FDR-corrected p-values. The average improvement
factor shows that pDis analysis (all genes) improves the results 33.3% compared to GSA.
Twelve target pathways were found to be significant in pDis analysis (all genes) while non of
the target pathways have significant FDR-corrected p-values in GSA. As shown, the average
p-value for the target pathways are lower (i.e. better) in the pDis analysis (all genes) than
in GSA.
23
GEO ID Target pathway GSEA pDis analysis (all genes) Improvement
p-values FDR ranks p-values FDR ranks Compared to
GSEA
1 GSE1297 Alzheimer’s Disease 5e-06 4e-05 5.75 5e-06 5.7e-05 4.74 +0.5
2 GSE5281 Alzheimer’s Disease 5e-06 4e-05 3.59 5e-06 3.6e-05 7.29 -0.5
3 GSE5281 Alzheimer’s Disease 5e-06 4e-04 5.75 5e-06 2.6e-05 9.85 -0.5
4 GSE5281 Alzheimer’s Disease 5e-06 4e-05 7.19 5e-06 2.6e-05 9.85 -0.5
5 GSE20153 Parkinson’s disease 0.995 1 96.40 0.002 0.008 21.53 +1
6 GSE20291 Parkinson’s disease 5e-06 4e-05 6.83 5e-06 2.2e-05 11.67 -0.5
7 GSE8762 Huntington’s disease 5e-06 0.08 6.83 5e-06 1.6e-05 15.32 +1
8 GSE4107 Colorectal Cancer 0.081 0.171 35.25 0.002 0.009 20.43 +1
9 GSE8671 Colorectal Cancer 0.312 0.625 56.83 0.116 0.248 46.71 -0.5
10 GSE9348 Colorectal Cancer 0.118 0.283 33.81 0.054 0.172 31.02 +0.5
11 GSE14762 Renal Cancer 0.148 0.261 45.32 0.029 0.062 46.71 -0.5
12 GSE781 Renal Cancer 0.356 0.584 58.27 0.998 0.998 100 -0.5
13 GSE15471 Pancreatic Cancer 0.020 0.038 38.84 0.168 0.247 67.88 -1
14 GSE16515 Pancreatic Cancer 0.002 0.019 16.54 0.121 0.242 49.63 -1
15 GSE19728 Glioma 0.069 0.121 50.35 5e-06 2.2e-05 11.31 +1
16 GSE21354 Glioma 0.114 0.248 43.88 5e-06 2.1e-05 12.04 +1
17 GSE6956 Prostate Cancer 0.023 0.170 22.30 0.031 0.124 24.45 -0.5
18 GSE6956 Prostate Cancer 0.016 0.068 17.98 0.001 0.013 6.56 +1
19 GSE3467 Thyroid Cancer 0.463 0.682 71.22 0.018 0.061 28.83 +0.5
20 GSE3678 Thyroid Cancer 0.182 0.353 40.28 0.201 0.364 54.38 -0.5
21 GSE9476 Acute myeloid leukemia 0.4662 0.808 56.83 5e-06 9.7e-05 2.92 +1
22 GSE18842 Non-Small Cell Lung Can-
cer
0.414 0.727 63.30 0.496 0.635 78.10 -0.5
23 GSE19188 Non-Small Cell Lung Can-
cer
0.870 0.995 87.76 0.874 0.925 93.43 -0.5
24 GSE3585 Dilated cardiomyopathy 0.874 1 88.48 0.093 0.364 25.54 +0.5
Average 0.23 0.34 39.98 0.133 0.186 32.51 +2.5/24=10%
Table 2.5: The ranks and the p-values of the 24 target pathways for GSEA and pDis analysis
(all genes). The improvement factor based on Figure 2.3 is calculated for each dataset con-
sidering 5% significance threshold using FDR-corrected p-values. The average improvement
factor shows that pDis analysis (all genes) improves the results 10% compared to GSEA. As
shown, the average p-value and rank for the target pathways are lower (i.e. better) in the
pDis analysis (all genes) than in GSEA.
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GEO ID Target pathway SPIA (all genes) pDis analysis (all genes) Improvement
p-values FDR ranks p-values FDR ranks Compared to
SPIA (all genes)
1 GSE1297 Alzheimer’s Disease 0.095 0.414 22.72 5e-06 5.7e-05 4.74 +1
2 GSE5281 Alzheimer’s Disease 0.661 0.880 73.48 5e-06 3.6e-05 7.29 +1
3 GSE5281 Alzheimer’s Disease 0.060 0.255 23.10 5e-06 2.6e-05 9.85 +1
4 GSE5281 Alzheimer’s Disease 0.332 0.695 47.72 5e-06 2.6e-05 9.85 +1
5 GSE20153 Parkinson’s disease 0.021 0.170 11.36 0.002 0.008 21.53 +1
6 GSE20291 Parkinson’s disease 0.020 0.174 10.98 5e-06 2.2e-05 11.67 +1
7 GSE8762 Huntington’s disease 0.955 0.992 96.21 5e-06 1.6e-05 15.32 +1
8 GSE4107 Colorectal Cancer 0.010 0.101 9.84 0.002 0.009 20.43 +1
9 GSE8671 Colorectal Cancer 0.991 1.00 98.48 0.116 0.248 46.71 +0.5
10 GSE9348 Colorectal Cancer 0.197 0.433 45.45 0.054 0.172 31.02 +0.5
11 GSE14762 Renal Cancer 0.004 0.025 15.90 0.029 0.062 46.71 -1
12 GSE781 Renal Cancer 0.074 0.338 21.21 0.998 0.998 100 -0.5
13 GSE15471 Pancreatic Cancer 0.039 0.125 30.68 0.168 0.247 67.88 -0.5
14 GSE16515 Pancreatic Cancer 0.046 0.144 31.81 0.121 0.242 49.63 -0.5
15 GSE19728 Glioma 0.301 0.502 59.84 5e-06 2.2e-05 11.31 +1
16 GSE21354 Glioma 0.026 0.118 21.96 5e-06 2.1e-05 12.04 +1
17 GSE6956 Prostate Cancer 0.083 0.543 15.15 0.031 0.124 24.45 -0.5
18 GSE6956 Prostate Cancer 0.027 0.294 8.71 0.001 0.013 6.56 +1
19 GSE3467 Thyroid Cancer 0.936 0.990 93.93 0.018 0.061 28.83 +0.5
20 GSE3678 Thyroid Cancer 0.951 0.977 94.69 0.201 0.364 54.38 +0.5
21 GSE9476 Acute myeloid leukemia 0.512 0.793 62.87 5e-06 9.7e-05 2.92 +1
22 GSE18842 Non-Small Cell Lung Can-
cer
0.294 0.591 49.24 0.496 0.635 78.10 -0.5
23 GSE19188 Non-Small Cell Lung Can-
cer
0.712 0.824 86.36 0.874 0.925 93.43 -0.5
24 GSE3585 Dilated cardiomyopathy 0.471 0.801 57.95 0.093 0.364 25.54 +0.5
Average 0.325 0.507 45.40 0.133 0.186 32.51 +11/24=43.75%
Table 2.6: The ranks and the p-values of the 24 target pathways for SPIA (all genes) and
pDis analysis (all genes). The improvement factor based on Figure 2.3 is calculated for each
dataset considering 5% significance threshold using FDR-corrected p-values. The average
improvement factor shows that pDis analysis (all genes) improves the results 43.75% com-
pared to SPIA (all genes). Twelve target pathways were found to be significant in pDis
analysis (all genes) while only one target pathway have significant FDR-corrected p-values
in SPIA (all genes). As shown, the average p-value and rank for the target pathways are
lower (i.e. better) in the pDis analysis (all genes) than in SPIA (all genes).
25
in the condition under study. We chose to perform detailed analysis of the first neurodegen-
erative disease as it appears in Table 2.1. We provide the information about the p-values of
all the analyzed pathways with FDR-corrected p-value lower that 5% for the dataset study-
ing Alzheimer’s disease [17] (see Table 2.7). The pathways with bold font in each table are
known to be related to that disease based on existing literature. We can see that most of
the significant pathways are biologically meaningful in the condition studied, showing high
precision in the results. These results indicate that the proposed method is able to report
the target pathways as more significant and ranked higher, compared to the state-of-the-art
methods for pathway analysis, as well as it is able to report as significant the pathways that
are known to be associated to a given disease.
Name ID p-values FDR ranks references
1 Alzheimer’s disease 05010 5e-06 5e-05 4.74
2 Cytokine-cytokine receptor interaction 04060 5e-06 5e-05 4.74 [109]
3 Glutamatergic synapse 04724 5e-06 5e-05 4.74 [38]
4 GABAergic synapse 04727 5e-06 5e-05 4.74 [76]
5 Dopaminergic synapse 04728 5e-06 5e-05 4.74 [84]
6 Long-term depression 04730 5e-06 5e-05 4.74 [98]
7 Endocrine and other factor-regulated calcium reabsorption 04961 5e-06 5e-05 4.74
8 Parkinson’s disease 05012 5e-06 5e-05 4.74 [5, 24]
9 Amyotrophic lateral sclerosis (ALS) 05014 5e-06 5e-05 4.74 [85]
10 Huntington’s disease 05016 5e-06 5e-05 4.74 [24, 44]
11 Vibrio cholerae infection 05110 5e-06 5e-05 4.74
12 Pathogenic Escherichia coli infection 05130 5e-06 5e-05 4.74
13 Oocyte meiosis 04114 1e-03 0.01 10.95
14 Long-term potentiation 04720 1e-03 0.01 10.95 [67, 138]
15 Retrograde endocannabinoid signaling 04723 1e-03 0.01 10.95 [89]
16 Gastric acid secretion 04971 1e-03 0.01 10.95
17 Pancreatic secretion 04972 1e-03 0.01 10.95
18 VEGF signaling pathway 04370 2e-03 0.01 13.87 [48, 105]
19 Epithelial cell signaling in Helicobacter pylori infection 05120 2e-03 0.01 13.87
20 Systemic lupus erythematosus 05322 2e-03 0.01 13.87
21 Salmonella infection 05132 3e-03 0.02 15.33
22 Calcium signaling pathway 04020 0.01 0.03 16.79 [22, 153]
23 Salivary secretion 04970 0.01 0.03 16.79
24 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 05412 0.01 0.03 16.79
25 Gap junction 04540 0.01 0.03 18.25 [82, 124]
26 Phosphatidylinositol signaling system 04070 0.01 0.04 18.98 [14, 158]
27 Morphine addiction 05032 0.01 0.04 19.71
28 Protein processing in endoplasmic reticulum 04141 0.01 0.04 20.80 [142]
29 Shigellosis 05131 0.01 0.04 20.80
30 Renal cell carcinoma 05211 0.01 0.05 21.90
Table 2.7: The resulting ranks and p-values for all the pathways with FDR-corrected p-value
lower than 5% from analyzing the dataset studying Alzheimer’s disease [17]. We studied the
association of these top pathways to Alzheimer’s disease. The pathway shown in red is the
target pathway with the name corresponding to the disease under study. The bold pathways
are the ones with known association with Alzheimer’s disease based on existing literature.
The number of bold and red pathways represents the number of true positives found by the
method. Here we can see 16 true positives with FDR-corrected p-value lower than 5%.
26
2.4.2 Results of the target pathways for eight yeast knock-out datasets
We also validate our approach using eight datasets that come from experiments study-
ing eight yeast knock-out genes. We obtained the KEGG signaling pathways for yeast from
the “ROntoTools” R package version 1.2.0 [146] as included in Bioconductor version 2.12
released on April 4, 2013. We used all pathways that have at least one interaction of type
activation, inhibition, expression, or repression. There are nine such yeast pathways in
KEGG. We used the data provided by [61] as our wild type and knock-out sample. These
are contained in the datasets GSE42215 [61] and GSE42527 [61], respectively. We selected
eight knock-out datasets whose knock-out genes belong to at least one pathway considered in
the analysis. The log2-fold changes for each knock-out sample were calculated by comparing
expression levels of that sample with the wild type samples. Each dataset was processed as
described above. We performed the pDis analysis (all genes), SPIA (all genes) and GSA,
for each of the eight knock-out samples using the calculated log2-fold changes. The target
pathways for each knock-out data are the pathways that include the knock-out genes. The
ranks and p-values of the target pathways for eight yeast knock-out datasets are shown in the
Tables 2.8 and 2.9. The data show an improvement of about 55% with respect to SPIA (all
genes) and an improvement of about 20% with respect to GSA. The GSEA results were not
included in the comparison on the knock-out datasets because GSEA analysis is not available
for yeast pathways. The statistical tests are performed as one-tail in order to test whether
the ranks and p-values of target pathways in proposed methods are significantly lower than
the reference methods. The proposed method yields significantly better results compared
to SPIA (all genes) in terms of both p-values (t-test p-value = 0.002) as well as ranks of
the target pathways (Wilcoxon test p-value = 0.01). The result show that pDis (all genes)
provides lower p-values (t-test p-value = 0.09) and lower ranks for the target pathways,
although not significantly (Wilcoxon test p-value = 0.36) when compared to GSA.
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knock-
out
genes
target pathway SPIA (all genes) pDis analysis (all genes) improvement
factors
p-values FDR ranks p-values FDR ranks compared
to SPIA
1 APC9 Cell cycle 0.422 1 3 0.133 0.411 2 +0.5
Meiosis - yeast 0.917 1 5 0.184 0.414 4 +0.5
2 TPK3 Meiosis- yeast 5e-06 4.5e-05 1 5e-06 4e-05 1 -
3 RGT2 Meiosis- yeast 0.075 0.225 3 0.001 0.009 1 +1
4 USA1 Protein processing in endoplasmic
reticulum
1 1 7.5 0.092 0.27 3 +0.5
5 TIF4631 RNA transport 1 1 7.5 0.084 0.756 1 +0.5
6 URM1 Sulfur relay system 0.048 0.306 1 0.040 0.36 1 +1
7 SSM4 Protein processing in endoplasmic
reticulum
1 1 7.5 0.004 0.018 2 +0.5
8 CUE1 Protein processing in endoplasmic
reticulum
1 1 7.5 0.208 0.624 3 +0.5
Average 0.606 0.725 4.77 0.082 0.318 2 5/9=55%
Table 2.8: The ranks and the p-values of the target pathways for SPIA (all genes) and
pDis analysis (all genes) using 8 yeast knock-out datasets. The improvement factor based
on Figure 2.3 is calculated for each dataset considering 5% significance threshold using
FDR-corrected p-values. The average improvement factor shows that pDis analysis (all
genes) improves the results 55% compared to SPIA (all genes). Three target pathways
were found to be significant after FDR-correction in pDis analysis (all genes) while only one
target pathways have significant FDR-corrected p-values in SPIA (all genes). As shown, the
average p-value and rank for the target pathways are lower (i.e. better) in the pDis analysis
(all genes) than in SPIA (all genes). The results show that pDis analysis (all genes) yields
significantly better p-values than SPIA (all genes) for the target pathways (p-value from
t-test = 0.002) as well as it has significantly lower ranks for the target pathways compared
to SPIA (all genes) (p-value from Wilcoxon test = 0.01).
knock-
out
genes
target pathway GSA pDis analysis (all genes) improvement
factors
p-values FDR ranks p-values FDR ranks compared
to GSA
1 APC9 Cell cycle 0.05 0.28 1 0.133 0.411 2 -0.5
Meiosis - yeast 0.06 0.28 2 0.184 0.414 4 -0.5
2 TPK3 Meiosis- yeast 0.40 0.63 5 5e-06 4e-05 1 +1
3 RGT2 Meiosis- yeast 0.98 0.98 9 0.001 0.009 1 +1
4 USA1 Protein processing in endoplasmic
reticulum
0.09 0.78 1 0.092 0.27 3 -0.5
5 TIF4631 RNA transport 0.78 0.88 6 0.084 0.756 1 +0.5
6 URM1 Sulfur relay system 0.02 0.09 2 0.040 0.36 1 +0.5
7 SSM4 Protein processing in endoplasmic
reticulum
0.04 0.43 1 0.004 0.018 2 +1
8 CUE1 Protein processing in endoplasmic
reticulum
0.04 0.31 1 0.208 0.624 3 -0.5
Average 0.27 0.51 3.1 0.082 0.318 2 2/9=22.2%
Table 2.9: The ranks and the p-values of the target pathways for GSA and pDis analysis
(all genes) using 8 yeast knock-out datasets. The improvement factor based on Figure 2.3
is calculated for each dataset considering 5% significance threshold using FDR-corrected
p-values. The average improvement factor shows that pDis analysis (all genes) improves
the results 22.2% compared to GSA. Three target pathways were found to be significant
after FDR-corrected-correction in pDis analysis (all genes) while no target pathways have
significant FDR-corrected p-values in GSA. As shown, the average p-value and rank for the
target pathways are lower (i.e. better) in the pDis analysis (all genes) than in GSA. The
results show that pDis analysis (all genes) yields better p-values than GSA for the target
pathways (p-value from t-test = 0.09) as well as it has lower ranks for the target pathways
compared to GSA (p-value from Wilcoxon test = 0.36).
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2.4.3 False positives under the null hypothesis
As we have demonstrated, the proposed method produces significantly lower p-values
for the target pathways compared with the existing methods, across the set of 24 datasets
used in the validation. However, lower p-values for the target pathways could be produced
if the new method indiscriminately lowered the p-values for all pathways, thus introducing
many false positives.
In order to show that this is not the case, we ran a number of experiments with
completely random data. In each of these experiments, a set of expression changes are
assigned to the genes from a random normal distribution with mean of zero and standard
deviation of 1. This was repeated 1,000 times and the p-values for the pathways were
computed in each iteration. The pathways’ p-values for these random datasets, produced
the distribution for the p-values under the null hypothesis. Null-hypothesis distributions were
also calculated for each target pathway and showed no abnormal tendencies. The distribution
of the pooled p-values for all pathways over the 1,000 iterations is shown in Figure 2.5. Both
the distribution of the pooled p-values, as well as all null distributions associated with each
individual target pathway were uniform, demonstrating that our method does not yield more
significant p-values for the target pathways by lowering all p-values. These distributions
demonstrate that the proposed method does not produce any more false positives than
appropriate for any significance threshold.
2.4.4 Results of the target pathways for weighted-pDis analysis
Most of the existing pathway analysis methods compute gene level statistics that are
then combined into a pathway level score. One key drawback is that the same gene statistic
is considered in all pathways containing that gene. This may be a suboptimal strategy since
a gene can play different roles in different pathways. Different approaches for estimating
the weights of fold changes of the genes are introduced in [126, 143, 144]. A recent method
was proposed to detect, quantify and correct the crosstalk effect between overlapping path-
ways [31]. We hypothesized that the performance of the proposed approach (pDis analysis)
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Figure 2.5: The null distribution of the p-values obtained from pDis analysis for all KEGG
signaling pathways (139 pathways) in 1,000 iterations. The input gene expression values were
chosen from a random normal distribution with mean of 0 and standard deviation of 1. The
histogram shows the null distribution of the pooled p-values. Uniform distributions were also
obtained for each individual target pathway (data not shown). The uniform distributions
prove that pDis analysis does not produce any more false positives than expected.
can be improved by considering effects of the crosstalk between pathways. The contributions
of the genes are calculated based on the given condition and the set of pathways. Here, we
investigate eliminating such crosstalk effect on the fold change of the genes based on the pro-
posed crosstalk coefficients, which represent the contributions of the genes in each pathway.
This contribution is estimated by the number of differentially expressed (DE) genes in the
overlapping pathways. A pathway is expected to have higher contribution if it has more DE
genes. For more details about the exact formula see Supplementary Material in [31].
We eliminate the crosstalk effect between pathways by weighing the fold changes of
the genes in different pathways, to which they belong, as follows:
new∆Eij = Pij ·∆Ei (2.10)
where, Pij is the weight of genei in pathwayj. The weighted fold change (new∆E) of a gene
in each pathway represents the corrected involvement of that specific gene in that specific
pathway.
The proposed approach is used in conjunction with the proposed pathway analysis
method, referred to as “weighted-pDis analysis”. The results are validated using the same
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Figure 2.6: The ranks (in the left column, lower is better) and negative log of p-values
of the target pathways (in the right column, higher is better) in the pDis and weighted-
pDis analysis. All human signaling pathways from KEGG (139 pathways) were used in the
comparisons. The box-plots show the results obtained for the target pathways in the 23
datasets shown in Table 2.1. The bold line in the box-plots represents the median of the
distribution. The red line represents the 5% significance level. These distributions show that
the weighted-pDis (in green) performs better than original pDis analysis.
approaches mentioned above, on 23 real datasets from experiments studying 12 different con-
ditions and are compared to the proposed pDis analysis. We could not analyzed “GSE20153”
due to a very small number of DE genes in that dataset (only 3).
The Figure 2.6 shows the distributions of the ranks and p-values of the target path-
ways in weighted and original pDis analysis. The paired t-test and the paired Wilcoxon test
were performed to compare the distributions of the ranks and p-values of target pathways
in each method (t-test p-value= 0.0008, Wilcoxon p-value= 0.05). The results show that
the p-values and ranks of the target pathways in weighted-pDis analysis are significantly
lower than original pDis analysis. The details of the results from each method and the
improvement factors of each dataset are shown in table 2.10.
2.4.5 Results of the target pathways for integrated pDis analysis
The current pathway analysis approaches take into consideration pathways as inde-
pendent entities. However, these pathways can share genes and interactions and therefore
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Target pathway pDis (cut-off) weighted-pDis (cut-off) Improvement
p-values FDR ranks p-values FDR ranks Compared to pDis
(cut-off)
1 Alzheimer’s Disease 0.73 0.99 70.83 5e-06 9e-05 3.03 +1
2 Alzheimer’s Disease 0.02 0.33 6.20 1.00 1.00 100.00 -0.5
3 Alzheimer’s Disease 0.01 0.20 2.99 0.18 0.29 61.19 -0.5
4 Alzheimer’s Disease 0.07 0.36 18.94 0.15 0.25 60.61 -0.5
5 Parkinson’s disease 0.42 0.80 50.48 0.46 0.99 36.67 +0.5
6 Huntington’s disease 0.42 0.52 79.66 0.04 0.37 8.47 +0.5
7 Colorectal Cancer 0.02 0.18 12.50 0.04 0.09 38.97 -0.5
8 Colorectal Cancer 0.35 0.77 44.12 0.03 0.07 36.03 +0.5
9 Colorectal Cancer 0.39 0.68 56.93 0.02 0.06 31.75 +0.5
10 Renal Cancer 0.48 0.79 61.31 0.02 0.07 30.66 +0.5
11 Renal Cancer 0.86 0.94 91.79 0.08 0.24 33.58 +0.5
12 Pancreatic Cancer 0.45 0.76 59.56 0.01 0.05 25.00 +1
13 Pancreatic Cancer 0.45 0.80 55.56 0.03 0.09 29.63 +0.5
14 Glioma 0.23 0.49 47.45 5e-06 0.02 18.25 +1
15 Glioma 0.34 0.56 61.03 5e-06 0.02 12.50 +1
16 Prostate Cancer 0.77 0.98 74.26 0.19 0.35 52.94 +0.5
17 Prostate Cancer 0.56 0.99 41.32 0.35 0.82 32.23 +0.5
18 Thyroid Cancer 0.57 0.93 58.52 0.18 0.30 59.26 -0.5
19 Thyroid Cancer 0.31 0.76 41.04 0.17 0.32 52.24 -0.5
20 Acute myeloid leukemia 5.51 0.06 0.83 0.29 0.52 55.12 -0.5
21 Non-Small Cell Lung Cancer 16.79 0.06 0.35 0.05 0.14 36.50 -0.5
22 Non-Small Cell Lung Cancer 31.39 0.18 0.56 0.05 0.13 39.42 -0.5
23 Dilated cardiomyopathy 69.89 0.58 0.83 0.03 0.65 4.30 +0.5
average 0.36 0.66 46.00 0.14 0.29 37.31 4.5/23=19.56%
Table 2.10: The ranks and the p-values of the 23 target pathways for pDis analysis and
wighted-pDis analysis. The improvement factor based on Fig. 2.3 is calculated for each
dataset considering the 5% significance threshold using FDR-corrected p-values. The average
improvement factor shows that wighted-pDis analysis improves 19.56% compared to pDis
analysis. As shown, the average p-value and rank for the target pathways are lower (i.e.
better) in weighted-pDis analysis than in pDis analysis.
affect each other. We investigated the results of our pathway analysis approach by consid-
ering the relations between pathways. We observed that some genes are included in more
than one pathway and have interactions with different genes based on the pathways in which
they exist. We looked at the global network of pathways as one single network. This global
network is an integration of all the genes, and their associated interactions, which includes
5,052 nodes and 27,811 interactions. This approach is introduced in [18]. The primary dis-
regulation for each gene is computed based on this global network, and then the score is
summed to calculate the score of each pathway separately. The results are validated using
the same procedure and datasets mentioned above.
The Figure 2.7 shows the distributions of the ranks and p-values of the target path-
ways in the integrated and original pDis analysis. The paired t-test and the paired Wilcoxon
test were performed to compare the distributions of the ranks and p-values of target path-
ways in each method (t-test p-value= 9.579e − 07, Wilcoxon p-value= 0.001). The results
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Figure 2.7: The ranks (in the left column, lower is better) and negative log of p-values
of the target pathways (in the right column, higher is better) in the pDis and Integrated-
pDis analysis. All human signaling pathways from KEGG (139 pathways) were used in the
comparisons. The box-plots show the results obtained for the target pathways in the 24
datasets shown in Table 2.1. The bold line in the box-plots represents the median of the
distribution. The red line represents the 5% significance level. These distributions show that
the Integrated-pDis (in pink) performs better than original pDis analysis.
show that the p-values of the target pathways in Integrated-pDis analysis are significantly
lower than original pDis analysis.
The details of the results from each method and the improvement factors of each
dataset are shown in table 2.11.
2.5 Conclusion
Here, we proposed a new topological pathway analysis method based on the amount
of perturbation associated with each individual gene. The proposed pDis analysis considers
the dis-regulation of each gene in every pathway to calculate a p-value with respect to
the distribution of the dis-regulation under the null hypothesis. The proposed method is
able to use either i) a pre-selected number of DE genes, pDis analysis (cut-off), or ii) the
entire list of measured expression levels, pDis analysis (all genes). The results showed that
the proposed method yields significant improvements with respect to the state-of-the-art
methods: SPIA, GSEA and GSA. Furthermore, we showed that the pDis analysis results are
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Target pathway pDis (cut-off) Integrated-pDis (cut-off) Improvement
p-values FDR ranks p-values FDR ranks Compared to pDis
(cut-off)
1 Alzheimer’s Disease 0.729 0.893 70.83 5e-04 0.005 5.12 +1
2 Alzheimer’s Disease 0.022 0.348 6.20 5e-04 0.003 7.22 +1
3 Alzheimer’s Disease 0.006 0.207 2.99 5e-04 0.005 4.51 +1
4 Alzheimer’s Disease 0.068 0.842 18.94 5e-04 0.007 3.61 +1
5 Parkinson’s disease 1.00 1.00 98.72 0.008 0.039 20.18 +1
6 Parkinson’s disease 0.425 1.00 50.48 5e-04 0.002 12.34 +1
7 Huntington’s disease 0.425 0.352 79.66 5e-04 0.003 6.92 +1
8 Colorectal Cancer 0.023 0.961 12.50 0.056 0.099 57.22 -0.5
9 Colorectal Cancer 0.351 0.217 44.12 0.031 0.070 44.87 -0.5
10 Colorectal Cancer 0.387 0.154 56.93 0.079 0.188 42.16 +0.5
11 Renal Cancer 0.482 0.147 61.31 5e-04 0.002 9.03 +1
12 Renal Cancer 0.859 1.00 91.79 0.061 0.154 39.45 +0.5
13 Pancreatic Cancer 0.451 0.573 59.56 0.0064 0.015 40.36 +1
14 Pancreatic Cancer 0.452 1.00 55.46 0.002 0.012 18.37 +1
15 Glioma 0.235 0.135 47.45 5e-04 0.002 12.56 +1
16 Glioma 0.342 0.360 61.03 5e-04 0.002 8.73 +1
17 Prostate Cancer 0.771 0.998 74.26 0.211 0.359 58.43 +0.5
18 Prostate Cancer 0.555 0.931 41.32 0.003 0.026 13.25 +1
19 Thyroid Cancer 0.570 0.790 58.52 0.106 0.213 50.00 +0.5
20 Thyroid Cancer 0.313 1.00 44.04 0.071 0.190 36.74 +0.5
21 Acute myeloid leukemia 0.064 0.795 1.20 0.002 0.80 22.89 -0.5
22 Non-Small Cell Lung Cancer 0.060 0.925 20.48 0.0009 0.93 12.65 +0.5
23 Non-Small Cell Lung Cancer 0.176 0.394 35.54 5e-04 0.39 9.33 +0.5
24 Dilated cardiomyopathy 0.577 1.00 69.89 0.107 0.258 41.56 +0.5
Average 0.389 0.668 48.19 0.031 0.070 24.07 15.5/24=64.5%
Table 2.11: The ranks and the p-values of the 24 target pathways for pDis analysis and
Integrated-pDis analysis. The improvement factor based on Fig. 2.3 is calculated for each
dataset considering the 5% significance threshold using FDR-corrected p-values. The average
improvement factor shows that Integrated-pDis analysis improves 64.5% compared to pDis
analysis. As shown, the average p-value and rank for the target pathways are lower (i.e.
better) in Integrated-pDis analysis than in pDis analysis.
significantly improved if the involvements of the gene in the pathways as well as, the relations
between pathways are taken into consideration. The comparisons have been performed with
a validation method that used 24 different datasets involving 12 different human diseases
and eight different datasets involving eight knocked out genes in yeast.
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CHAPTER 3: NEIGHBOR-NET ANALYSIS
3.1 Background
Understanding the mechanisms that cause changes in a phenotype requires identifying
genes that are disrupted and relationships between them. Current technologies allow us to
measure gene expression with unprecedented accuracy. Collecting such data across time
enables the inferences of gene interactions (i.e., how a change in the expression of a gene
affects other genes). There are many existing methods that extract information both from a
single comparison (i.e., a steady state) [19, 55, 71] or multiple comparisons across time (i.e.,
time series) [157].
First attempts to discover gene regulatory networks started as soon as the first mi-
croarray experiments were published. Microarray technology measures the messenger RNA
(mRNA) expression level of each gene. mRNAs are translated into proteins or transcription
factors (TF), so the activity of a protein is estimated by the corresponding mRNA production
which can be increased or decreased by the cell function. Assuming the mRNA expression
of each gene is correlated to its protein product, we can use microarray data to infer the
relations between genes and their products. Based on this assumption, the information from
protein-protein interaction and protein-DNA interaction databases can also be used as a
priori knowledge to predict the relations between genes [52, 78, 91]. These information can
be obtained from different resources [12, 46, 81].
The number of proposed methods to infer network from gene expression data is grow-
ing each year, but there is no established approach to validate their results. There are some
methods that use synthetic data to validate their results. The data is generated based on
a known network, and the results are expected to have overlaps with the known source.
However, many methods use real data to assess the proposed method. The ground truth
in analyzing the real data is unknown, which makes it very difficult to evaluate the results.
There are some methods that construct the gene regulatory network for simple organisms
(e.g. yeast). The relationships between genes in yeast is well known, so the results will be
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validated by being compared to the published literature based on how many true positives
the method is able to infer. Other methods, using more complex organisms, compare the
known interactions with their results and assess the methods based on the number of over-
laps. Another evaluation approach, to find the accuracy of a method, is using the constructed
networks as input for pathway analysis algorithms. The number of common genes between
each pathway/gene set and the constructed network can be considered as a factor to score
the pathways/gene sets. The most related pathways to the condition are expected to have
significant number of common genes if the constructed networks are accurate.
In Table 3.12, features of different methods are summarized to show the advantages
and disadvantages of their algorithms.
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3.2 Motivation
Understanding how genes interact with each other is the key to understand the on-
set and evolution of a disease, for instance. Therefore, there is a need for computational
algorithms able to construct network of active interactions by analyzing data. One of the
drawbacks of the existing curated pathways or gene interactions databases is that each in-
teraction is extracted from literature or experimentally validated by independent studies.
However, most such interactions were found in specific tissues and/or phenotype, and not
all studies employed the same tissue and/or phenotype.
Therefore, these independently identified interactions in the databases may not ex-
ist in actual phenotype or tissue studied in a subsequent experiment. Furthermore, new
phenomena may be involved in the tissue or phenotype currently being studied. Utilizing
only existing pathways from pathways databases or literature, limits one’s ability to discover
new phenomena and new interactions. In order to overcome such limitations, some existing
methods try to build the regulatory networks based on the correlation or the co-expression
existing in the given datasets [55, 71, 107, 157]. The networks resulting from such meth-
ods are specific to the condition under study, but the interactions identified are only based
on the genes’ expression level. This limitation can produce many false positives as well
as false negatives, because an interaction between two genes is not necessarily reflected in
the correlation between their expression levels. The interactions between genes can involve
an indirect relation between them via their protein products or their transcription factors,
and sometimes interactions take place on different time scales. Therefore, there is a need
for computational algorithms able to construct network of active interactions by analyzing
data in more sophisticated ways, by combining gene expression data with existing pathway
information, as well as with data from protein-protein interactions databases.
However, the integration of high throughput datasets such as gene expression data
with prior information about gene-gene interactions to find the networks specific to a pheno-
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type is still an open challenge [66]. Such methods identify the network of interactions that
is most relevant to a given phenotype based on the retrieved prior knowledge, referred to as
“active network”. This network is also known as “network hotspot” or “responsive subnet-
work” [86]. The active network, as part of a global interaction network, explains the sudden
changes in the genes activity or the characteristic of the phenotype in a given disease. This
network is identified based on the given data and can be considered the putative mechanism
involved in the given phenotype. The advantage of identifying active network is that it is
specific to the condition studied, as opposed to existing curated pathways that can describe
more generic knowledge, not necessarily applicable to the given condition.
The discovery of active network can lead to the identification of signature network
that is associated to a given disease, rather than a set of gene biomarkers. This can lead
to better understanding of the disease, diagnosis and more accurate treatment. Biomarker
networks can also achieve more predictive power to classify different diseases such as diabetes
or different types of cancer [86]. Furthermore, disease-specific networks can also be used to
predict drug target mechanisms and to find the response of patients to the drugs.
Based on a comprehensive review published by [86] the existing approaches aiming to
identify active network using prior knowledge of interactions, can be decided in three main
categories, as follows. The first category is the “significant-area-search” methods. In this cat-
egory the genes and interactions between them are scored based on the input data, and the
algorithm tries to find the group of genes and interactions with the highest score. The very
first methods in this category are jActiveModules [52] implemented in Cytoscape [116], and
Gene Network Enrichment Analysis (GNEA) [78]. The second category includes “diffusion-
flow” and “network-propagation” methods. The methods in this category attempt to find
the flow between genes with maximum scores in the existing networks. They identify sub-
set of genes and interactions that accumulate the highest score flows. The most widely
used methods in this category are NetWalker [65, 66], HotNet [140], and Physical Module
Networks [91]. The third category includes “cluster-based” methods. These methods use
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biclustering algorithms to find the interactions that are active in the given conditions. The
better known methods in this category are SAMBA [125] and SANDY [80].
In the following section, we propose a “network-propagation” algorithm that will
identify the maximum flow between genes through their immediately connected genes. This
method uses multiple steady state gene expression data that are collected from the same
phenotype. The use of multiple datasets allows the proposed approach to capture changes
of gene expression that might not be captured in any single dataset due for instance to
the snapshot nature of gene expression data. Gene-gene interactions will be obtained from
protein-protein interaction networks describing the relations between proteins and also from
experimentally curated signaling pathways. This method will use the neighborhood of each
gene to identify the propagation of disruption that flows through the system. The neighbor-
hood of each gene includes the genes that are directly connected to it based on the known
interaction networks.
We apply the method on multiple datasets from experiments studying colorectal can-
cer, renal cancer and prostate cancer. We assess the results in two ways: first, we assess
the enrichment of known biological pathways in the constructed network. This validation
process is similar to a gene set analysis approach introduced in [78]. In this reference [78], the
number of common genes between the associated gene sets to the given phenotype and the
identified network is used to validate the results. Similarly, we also consider here the number
of interactions overlapping between the constructed networks and known signaling pathways
that are associated to the disease investigated. Constructed networks that are significantly
enriched in these interactions are considered better than those that are less enriched in
such interactions. Second, we obtain a list of genes that are associated to the disease stud-
ied from DisGeNET [13, 101] and calculate the enrichment of each constructed network in
such disease-associated genes. DisGeNET integrates information from multiple public data
sources and literature ( 15 different resources) to identify gene-disease associations [101].
Networks that are significantly enriched in disease-associated genes are considered better
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than those that are less enriched in such genes. We compare our result with the results
of two widely used methods: NetWalker and HotNet, which also attempt to identify the
relevant biological mechanisms on a global network. We also compare our results with the
classical approach of considering just the union of differentially expressed (DE) genes in all
considered studies. The results of these comparisons show that the proposed method per-
forms better in constructing networks that are significantly relevant to the given diseases
based on the resulting genes and interactions.
3.3 Neighbor-net analysis
The approach presented here aims at finding networks of genes that capture the mech-
anisms that could explain the phenotype. The algorithm requires two types of data. The first
type is gene expression data that includes measured gene expression in the control samples
versus the investigated disease. The proposed approach uses multiple datasets relevant to
the same condition. This is important because each dataset is only a snapshot of the system
captured at a given moment in time. The changes in expression levels of the genes will be
better estimated by looking at multiple datasets, which represent different snapshots of the
same condition, and therefore provide much more information. The second type of data is the
prior information about gene-gene interactions that can be collected from different resources
describing any known interactions between genes, such as protein-protein interaction, gene
regulatory networks, and curated pathways. In addition, adding existing information about
known interactions allows us to estimate the potential effect of a condition on groups of in-
teracting genes that can ultimately constitute putative models of the mechanisms in action
in the given condition. The integration of these two types of data allows us to overcome
some of the limitations of existing methods.
The method starts with several existing datasets available for that disease. A list of
differentially expressed (DE) genes is calculated as the union of all sets of DE genes from
each such individual dataset.
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Figure 3.1: An overview of the proposed neighbor-net analysis. (a) The global network
combining all the known gene-gene interactions. The colors show three sample neighbor
networks for genes a, b and c. (b) The neighbor network for each gene is extracted from the
global known interactions. A global list of differentially expressed (DE) genes is obtained by
constructing the union of all genes found to be DE in at least one of the given datasets (based
on the their calculated log fold changes and p-values adjusted for multiple comparison). The
Fisher’s exact test is performed on all extracted neighbor networks based on the number of
DE genes they have. (c) The significant neighbor networks (FDR-corrected p-value lower
than 10%) are identified. (d) The constructed network which is built by integrating all
significant neighbor networks (shown in red).
The proposed approach then builds a “neighbor network” for each gene. The neighbor
network associated to each gene includes the gene itself, the genes immediately connected to
it and the interactions connecting them together based on known interactions from protein-
protein interaction databases such as a HPRD [99, 100], as well as from pathway databases
such as KEGG [58, 59]. This is done such that, even if none of the multiple datasets included
in the analysis captures the effect of the gene of interest, by looking at its immediate neigh-
borhood we can still detect changes that propagate from that gene. The neighbor network
is constructed exclusively from annotation databases, independently of the DE genes. In the
next step, we calculate the enrichment of each neighbor network based on the number of
DE genes they contain. The hypergeometric p-value for each neighbor network is calculated
based on the formula below:
po(x) = 1−
x−1∑
i=0
(
M
i
)
·
(
N −M
K − i
)
(
N
K
) (3.1)
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whereN is the total number of genes,K is the total number of DE genes andM is the number
of genes in each neighbor network. This p-value represents the probability of obtaining a
number of DE genes in the neighbor network that is equal or higher than the number observed
in the analysis, just by chance. Such p-values are computed for all neighbor networks and are
corrected for multiple comparisons with false discovery rate (FDR) method. The significant
neighbor networks, with FDR-corrected p-values lower than threshold (10%), are identified
and combined together to build the final constructed network. The genes and interactions
in the constructed network are the integration of all the genes and interactions extracted
from all the identified significant neighbor networks. This constructed network resulted
from the analysis can be considered as the active network that has the potential to capture
the mechanisms involved in the given disease. A summary of the method, referred to as
“neighbor-net analysis”, is shown in Figure 3.1.
3.4 Discussion and results
We present the results of our analysis on three different diseases (colorectal cancer,
renal cancer and prostate cancer). The method requires a set of datasets studying the same
disease under the same conditions. We selected three diseases with three or more datasets
available in GEO associated to each of the three cancer types. The results are compared with
the results obtained with three other approaches: HotNet [140], NetWalker [65, 66], and the
classical ORA [62]. The detailed results of each disease are shown in separate sections. The
gene expression data in each case is obtained from Gene Expression Omnibus (GEO) [9].
Using GEO2R [113], we compute a fold change and a p-value for each gene representing
the significance of the observed change in the expression levels between normal and disease
samples. The information about gene interactions is obtained from the Kyoto Encyclopedia
of Genes and Genomes (KEGG) (Release 72.0) [57, 58, 59] and Human Protein database
Reference (HPRD) (Release 9) [99, 100]. We chose to illustrate the proposed approach
using KEGG because it is well recognized and widely used (almost 7,800 citations) but this
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approach is completely independent of the pathway database used and can be used equally
well with Reactome [27, 56], BioCarta [90], etc. Similarly, the approach can be used with
any other protein-protein interaction database such as BioGRID [119], BIND [3], etc.
We collapsed all 173 available KEGG signaling pathways into one network with 5,052
nodes and 27,811 interactions. The protein-protein interaction (PPI) network downloaded
from HPRD includes 9,672 nodes and 39,233 interactions. Combing these two networks
results a global graph with 11,086 nodes and 62,934 interactions. The neighbor networks are
built for each gene and the associated p-values are computed to represent the significance of
their enrichment in the list of DE genes. The constructed network for each case study is the
integration of all significant neighbor networks.
There is no universally accepted validation method to assess the accuracy of the
constructed networks. Similar to a previous study [78], we evaluate the results by perform-
ing pathway enrichment analysis based on the edges overlapping between the constructed
network and pathways to identify what known biological mechanisms are captured. Such
analysis allows us to validate the parts of the constructed network that are obtained from
existing pathways known to be involved in the given disease. The hypergeometric p-value
for each pathway is computed based on the number of common edges it has with the con-
structed network. The ranked list of significant pathways for each case study will show which
pathways are more enriched in the constructed network. For each disease, we consider the
pathway that was created in order to explain that particular disease as the “target pathway”
(e.g. Colorectal cancer pathway is the target pathway for colorectal cancer). We validate the
constructed network using the rank of target pathway in the reported list of pathways sorted
by p-values corrected for multiple comparisons. The constructed network is more relevant
to the investigated disease if the rank of the target pathway is lower and the corresponding
p-value is more significant [126]. Note that other truly impacted pathways may be present
in this list for legitimate reasons.
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(a) (b) (c) (d)
Figure 3.2: An overview of the two evaluation processes for the constructed network. (a) The
constructed network which is built by integrating all significant neighbor networks (shown
in red). (b) We start the evaluation process by looking at the enrichment of each KEGG
pathway in edges also present in the constructed network. The red edges in each pathway
represent the edges overlapping between that pathway and the constructed network. The
significance of enrichment of each pathway is calculated based on the number of such edges.
(c) Pathways are ranked using their enrichment p-values. (d) The second evaluation process
calculates an enrichment p-value for each constructed network. This p-value characterizes
the enrichment of each constructed network in genes that are known to be associated to the
investigated disease based on DisGeNET. Lower p-values represent a significant enrichment
of the constructed network in nodes known to be associated with the disease.
In addition, we also evaluate the results by using the DisGeNET database [13, 101] to
determine how many genes in the network are known to be related to the given condition. A
p-value representing the significance of the number of identified genes known to be associated
to the investigated disease in the constructed network is computed. A lower p-value will mean
that the method identifies genes that are more relevant to the disease and therefore, that the
constructed network is more likely to describe the mechanism involved in that disease. Both
evaluation approaches are summarized in Figure 3.2. The results described in the following
sections show that the proposed method performs better in both evaluation processes in
comparison to all reference methods.
3.4.1 Colorectal cancer
We analyze five gene expression datasets studying colorectal cancer from GEO [9]
(GSE4173, GSE9348, GSE21510, GSE32323 and GSE8671). A global list of differentially
expressed (DE) genes is obtained by selecting the genes with an absolute value of log2 fold
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change higher than 1.5 and adjusted p-value lower than 0.01 in at least one dataset. The
union of DE genes includes 2,968 genes out of 19,852 total genes in the five experiments.
We perform our analysis on selected DE genes. Based on the calculated hypergeometric
p-values for all neighbor networks, 20 of them are significantly enriched in the given list
of DE genes. The constructed network is a global graph that integrates all the significant
neighbor networks. It includes 144 genes and 251 interactions and is shown in Figure 3.3.
This network can be seen as most likely to include the mechanisms involved in colorectal
cancer.
The edges overlapping between each KEGG signaling pathway and the constructed
network are identified. The probability of having the observed number of these edges just
by chance is calculated for every KEGG pathway. The list of KEGG pathways that are
significantly enriched in edges from the constructed network is shown in Table 3.13. This
table shows that the constructed network includes a significant number of edges from the
target pathway. In fact, the Colorectal cancer pathway is ranked 3rd and it has a significant
number of edges in common with the constructed network. The two other pathways that are
ranked higher than the Colorectal cancer pathway are the Hippo signaling pathway and the
Wnt signaling pathway. There is a extensive evidence that both Hippo signaling pathway [10,
20, 94], as well as Wnt signaling pathway [15, 23, 106] are very important in colorectal cancer.
Figure 3.4 shows the edges from the network built by the proposed algorithm, as they
appear in the context of existing KEGG pathways. Some of the gene interactions (edges) in
this figure, appear multiple times in various significant KEGG pathways.
Interestingly, these edges from the network built by the proposed neighbor-net analy-
sis describe a well known mechanism known to be involved in colorectal cancer. The β-catenin
protein is a very well-known protein that has important impacts on developing colorectal
cancer [88]. It is produced by gene “CTNNB1”. This gene is one of the parent nodes in
the green network present in 9 out of the 10 significant pathways shown in Figure 3.4. No-
tably, this gene is not identified as a differentially expressed gene by classical approaches
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Figure 3.3: The active network that describes the putative mechanisms involved in colorectal
cancer. The five subnetworks shown above include 144 nodes and 251 edges. The 130 red
edges represent the interactions that exist in significantly enriched KEGG pathways. The
17 edges shown in blue are present in KEGG pathways that are not significantly enriched
in edges from this network. The 70 genes shown in green are known to be associated to
colorectal cancer based on the DisGeNET database.
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(a) Hippo signaling pathway, anti-
apoptotic and pro-proliferation
(b) Wnt signaling pathway (c) Colorectal cancer pathway
(d) Thyroid cancer (e) Endometrial cancer (f) Arrhythmogenic right
ventricular cardiomyopa-
thy (ARVC)
(g) Calcium signaling path-
way
(h) Melanogenesis (i) Pathways in cancer (j) Prostate cancer
Figure 3.4: The edges overlapping between the identified active network in colorectal cancer and
each significantly enriched KEGG signaling pathways. The green genes represent the genes that are
associated to colorectal cancer based on DisGeNET database and green edges represent the common
edges in more than 33% of the significant pathways. The common network with gene “CTNNB1”
as a parent node is found in 9 out of 10 significant pathways. This gene produces β-catenin protein
which is one of the important proteins that trigger colorectal cancer.
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significant pathway FDR-corrected p-value references
Hippo signaling pathway 2.1e-104 [10, 20, 94]
Wnt signaling pathway 5.5e-22 [15, 23, 106]
Colorectal cancer pathway 3.7e-17
Thyroid cancer 1.8e-15
Endometrial cancer 2.4e-12
Arrhythmogenic right ventricular cardiomy-
opathy (ARVC)
6.4e-08
Calcium signaling pathway 5.7e-07 [69]
Melanogenesis 7.05e-06
Pathways in cancer 2.8e-03
Prostate cancer pathway 4.3e-03
Table 3.13: A list of significantly enriched pathways (FDR-corrected p-value < 0.05). These
pathways are significantly enriched in the network resulted from neighbor-net analysis. The
bold pathway is the target pathway in colorectal cancer. The third column shows the refer-
ences explaining the association of the respective pathways to colorectal cancer.
in any of the datasets so the classical approach of focusing on differentially express genes
would not be able to identify this mechanism. The interactions between “CTNNB1” and
its downstream genes,“LEF1”, and “TCF7L1”, are part of the network built by the proposed
approach, network that is present in most of the significant KEGG pathways. These genes
are immediately connected to other genes such as “MYC”, “CCND1”, and “BIRC5” that have
important roles in the evolution of colorectal cancer through a number of cell functions (e.g.
proliferation, apoptosis) [75, 88].
We also compare our result with the results produced by NetWalker and HotNet.
Both methods are widely used to construct networks of genes that are meant to describe the
active modules in a given phenotype. NetWalker is built based on an algorithm introduced
in [65, 66]. It accepts as input a list of all genes in the analysis but it requires the selection
of a specific group as “seeds”. We selected as seeds the genes that are differentially expressed
(fold change higher than 1.5 and adjusted p-value lower than 0.01) in at least one of the
datasets. NetWalker uses multiple resources such as KEGG, REACTOME interactions, and
literature based gene regulatory networks, as prior knowledge. The output of this method is
a network in which nodes represent genes, and edges represent interactions between them.
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This network is claimed to explain the mechanisms involved in the investigated disease.
The result of NetWalker for colorectal cancer datasets is a network that includes 901 genes
and 3,028 interactions. The p-value representing the significance of the number of edges
overlapping between this network and Colorectal cancer pathway is 0.99 (see Table 3.14).
This p-value shows that the network constructed by NetWalker is not overlapping in any
significant way with the KEGG pathway that describes the phenomena involved in this type
of cancer.
We also compare the results with HotNet [140] that also constructs a network from
known protein-protein interaction (PPI) network by considering the degree (number of links)
of each gene together with a gene’s score that shows the significance of change in its expression
level. We use the genes’ negative log of p-values as their associated scores. The minimum
p-value for each gene in five datasets is used to compute the scores. HotNet requires a
threshold for selecting the important networks. The authors provide an algorithm that
suggests 5 different thresholds for the given data. We use the minimum threshold suggested
by the algorithm. The constructed network includes 215 genes and 175 interactions. The
p-value representing the enrichment of the target pathway in the constructed network is 1.0
(see Table 3.14). In other words, the network constructed by HotNet does not overlap in
any significant way with the colorectal cancer pathway from KEGG, suggesting that this
constructed network does not capture many of the phenomena considered to be central to
the colorectal cancer development by the KEGG’s authors.
We also compare the enrichment of the target pathway in the network constructed
from the proposed method with the results of over representation analysis (ORA) which is a
classical pathway analysis method [62, 87]. ORA takes into consideration the number of DE
genes observed in each pathway and calculates the probability of observing this number just
by chance. The analysis is performed on the union of DE genes in all datasets considered.
The rank and the p-value of the target pathway representing its enrichment in the list of DE
genes is calculated and shown in Table 3.14.
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Colorectal cancer
method rank FDR-corrected p-value
neighbor-net analysis 3 3.7e-17
NetWalker 22 0.99
HotNet 95 1.0
ORA 96 0.37
Table 3.14: The ranks and p-values of the target pathway (Colorectal cancer pathway) in
neighbor-net analysis and three other methods. The p-values represent the significance
of the enrichment of the Colorectal cancer pathway in the identified active network. The
comparisons show that neighbor-net analysis reports the target pathway more significant
and highly ranked.
We also evaluate the results by assessing the number of nodes in each constructed
network that are known to be associated to the investigated disease. We compare the genes
in the identified active network with the genes known to be associated to colorectal cancer,
obtained from the DisGeNET database. The number of associated genes to colorectal cancer
from this database is 2,277. Based on the extracted associated genes 70 genes out of 144
genes reported by the neighbor-net analysis are known to be associated to colorectal cancer
(48%). The percentage of the genes associated to the colorectal cancer in the network
constructed by neighbor-net analysis is higher compared to all the reference methods. This
means that the neighbor-net analysis is able to identify a higher proportion of genes related
to colorectal cancer in comparison to other methods (see Table 3.15). Also, the computed p-
value that represents the significance of enrichment of such genes in the constructed network
in neighbor-net analysis is also highly significant (8.4e-15).
The p-values of observing the number of associated genes to colorectal cancer, just by
chance, as well as the percentages of such genes in the lists of genes reported by NetWalker,
HotNet and selected DE genes are shown in Table 3.15.
The lower p-values represent more significant enrichment of the genes associated to
colorectal cancer in the constructed network. The p-values show that the selected DE genes
and the list of genes resulted from NetWalker are also significantly enriched in the genes
associated to colorectal cancer. However, the percentage of such genes in the total list of
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Colorectal cancer
method #selected
genes
#colorectal
cancer genes
% p-value
neighbor-net analysis 144 70 48% 8.4e-15
NetWalker 901 283 31% 5.5e-18
HotNet 215 46 21% 0.23
Selected DE genes 2968 552 18% 5.8e-27
Table 3.15: The statistical analysis of the results from neighbor-net analysis and all the
methods compared in colorectal cancer. The columns show: the number of genes in the
identified active network reported by each method, the number of associated genes to col-
orectal cancer based on information obtained from DisGeNET [101], the percentages of the
genes known to be associated to colorectal cancer in the total number of identified genes
in each constructed networks, and the corresponding p-values for the enrichment in each
method. The p-value of observing the given number of genes that are associated to colorec-
tal cancer in the constructed network is highly significant in the neighbor-net analysis. The
percentage of the associated genes in the constructed network in also higher compared to all
three existing methods.
identified genes by neighbor-net analysis is higher compared to all other methods. The sta-
tistical analysis shows that neighbor-net analysis performs better than the existing methods
in both evaluation approaches. Essentially, the neighbor-net analysis is able to find more
associated genes to colorectal cancer compared to NetWalker, HotNet and the enrichment
approach, as well as more interactions relevant to colorectal cancer based on number of
overlaps with the Colorectal cancer pathway.
3.4.2 Renal cancer
We analyze three gene expression datasets studying renal cancer from GEO (GSE14762,
GSE6344, and GSE781). A list of differentially expressed genes is obtained by selecting the
genes with an absolute value of log2 fold change higher than 1.5 and adjusted p-value lower
than 0.01 in at least one dataset. The union of these DE genes includes 1,223 genes out of
18,113 total genes in the three experiments. We perform our analysis on selected DE genes.
Based on the calculated hypergeometric p-value for all neighbor networks, 69 of them are
significantly enriched in the given list of DE genes. The constructed network, which is an
integration of all significant neighbor networks, includes 663 genes and 1,552 interactions
(see Figure 3.5).
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We apply the same evaluation approaches for this case study. The list of KEGG
pathways that are significantly enriched in edges from the constructed network is shown
in Table 3.16. The “Renal cell carcinoma pathway”, which is the target pathway in renal
cancer, is reported as significant. Most of the significant pathways that are ranked higher
than the target pathway are also very important in developing renal cancer. (Antigen pro-
cessing and presentation [1, 114], HIF-1 signaling pathway [77, 104], Jak-STAT signaling
pathway [43, 123], Endocytosis pathway [33, 92] and Aldosterone-regulated sodium reabsorp-
tion pathway [8]).
Figure 3.6 shows the edges from the network built by the proposed algorithm, as they
appear in the context of existing KEGG pathways. One of the hub genes in the constructed
network is gene “HIF1A” that produces protein “HIF-α”. This gene also appears in “Renal cell
carcinoma pathway”. HIF1A is recognized as having an important function in development
of renal cancer [41, 139]. However, it is not identified as a differentially expressed gene by
classical approach in any of the three studying datasets. The interactions between this gene
and its downstream genes, which are present in the constructed network, play important
roles in renal cancer [47]. These interactions also appear in two of the significant KEGG
pathways. Identifying such interactions in the constructed network highlights the fact that
the constructed network resulted from neighbor-net analysis is very relevant to renal cancer
and can indeed capture the mechanisms involved in development of this type of cancer.
We compare the result of the neighbor-net analysis with the results of the classical
approach of selecting DE genes, NetWalker, and HotNet. The ranks and the p-values repre-
senting the significance of the enrichment of the target pathway in all the methods are shown
in Table 3.17. The rank of “Renal cell carcinoma pathway” is much lower (8th compared
to 94th and higher), and its corresponding p-value is more significant (2.6e − 03 compared
to 0.51 and higher) in neighbor-net analysis compared to all reference methods. We also
compare the genes in the constructed network with the genes known to be associated to
renal cancer obtained from DisGeNET database. The number of associated genes to renal
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(a) Antigen processing and presentation (b) Prolactin signaling pathway
(c) HIF-1 signaling pathway (d) Jak-STAT signaling pathway (e) Tuberculosis
(f) Endocytosis (g) Aldosterone-regulated sodium re-
absorption
(h) Renal cell carcinoma
Figure 3.6: The edges overlapping between the identified active network in renal cancer and each
significantly enriched KEGG signaling pathways. The green genes represent the genes that are
associated to renal cancer based on DisGeNET database. Gene “HIF1A”, which is a hub node in the
constructed network and exists in pathways HIF-1 signaling pathway and Renal cell carcinoma has
a known important function in development of renal cancer. All the hub genes in each significant
pathways have important impacts in renal cancer (see references in Table 3.16).
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significant pathway FDR-corrected p-value references
Antigen processing and presentation 1.1e-244 [1, 114]
Prolactin signaling pathway 2.4e-52
HIF-1 signaling pathway 1.1e-39 [77, 104]
Jak-STAT signaling pathway 6.8e-39 [43, 123]
Tuberculosis pathway 1.3e-23
Endocytosis pathway 8.4e-23 [33, 92]
Aldosterone-regulated sodium reabsorp-
tion pathway
5.4e-13 [8]
Renal cell carcinoma pathway 2.6e-03 -
Table 3.16: A list of significantly enriched pathways (FDR-corrected p-value < 0.05) in renal
cancer. These pathways are significantly enriched in the network resulted from neighbor-net
analysis. The bold pathway is the target pathway in renal cancer. The last column shows
the references explaining the association of the respective pathways to renal cancer.
cancer from this database is 1,220. Based on the extracted genes, 199 genes out of 663
genes in the constructed network are known to be associated to renal cancer (30%). The
percentage of such genes in the total list of resulted genes in the neighbor-net analysis is
higher compared to all reference methods. The p-values of observing the number of genes
associated to renal cancer in the list of genes reported by each method just by chance are
shown in Table 3.18. The table shows the results of the proposed method have both the most
significant p-value, as well as the highest percentage of genes known to be associated with
renal cancer. In summary, the comparisons show that the proposed method is able to find
more known renal cancer genes in the constructed network compared to NetWalker, HotNet
and classical approach. The proposed method also identifies more interactions related to
renal cancer based on number of overlaps with the Renal cancer pathway.
3.4.3 Prostate cancer
We analyze four gene expression datasets studying prostate cancer from GEO (GSE6956
African and Caucasian, GSE55945, and GSE45016). A list of differentially expressed genes
is obtained by selecting the genes with an absolute value of log2 fold change higher than
1 and adjusted p-value lower than 0.05 in at least one dataset. The union of these DE
genes includes 2,305 genes out of 19,851 total genes in the four experiments. We perform
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Renal cancer
method rank FDR-corrected p-value)
neighbor-net analysis 8 2.6e-03
NetWalker 106 1.0
HotNet 96.5 1.0
ORA 94 0.52
Table 3.17: The ranks and p-values of the target pathway (renal cancer) in neighbor-net
analysis and three other methods. The p-values represent the significance of the enrichment
of the renal cancer pathway in the identified active network. The comparisons show that
neighbor-net analysis reports the target pathway more significant and highly ranked.
Renal cancer
method #selected
genes
#renal cancer
genes
% p-value
neighbor-net analysis 663 198 30% 1.9e-41
NetWalker 424 82 19% 6.7e-07
HotNet 329 62 18% 2.8e-05
Selected DE genes 1223 189 15% 3.2e-22
Table 3.18: The statistical analysis of the results from neighbor-net analysis and all the
methods compared in renal cancer. The columns show: the number of genes in the identified
active network reported by each method, the number of associated genes to renal cancer
based on information obtained from DisGeNET [101], the percentages of the genes known
to be associated to renal cancer in the total number of identified genes in each constructed
networks, and the corresponding p-values for the enrichment in each method. The p-value of
observing the given number of genes that are associated to renal cancer in the constructed
network is highly significant in the neighbor-net analysis. The percentage of the associated
genes in the constructed network in also higher compared to all three existing methods.
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significant pathway FDR-corrected p-value references
Focal adhesion 4.0e-30 [68, 122]
Estrogen signaling pathway 2.4e-18 [26, 115]
Endocytosis 1.5e-17 [39, 137]
ErbB signaling pathway 4.3e-14 [42]
Adherens junction 1.5e-13 [21, 103]
Glioma 1.1e-11
Ras signaling pathway 2.6e-09 [6, 96, 152]
Choline metabolism in cancer 2.5e-08 [28, 37]
Proteoglycans in cancer 7.6e-08 [34, 40]
Rap1 signaling pathway 1.0e-07 [4]
Prostate cancer pathway 2.4e-07 -
Table 3.19: Top 11 significant pathways (FDR-corrected p-value < 0.05) in prostate cancer.
These pathways are significantly enriched in the network resulted from neighbor-net analysis.
The bold pathway is the target pathway in prostate cancer. The third column shows the
references explaining the association of the respective pathways to prostate cancer.
our analysis on selected DE genes. Based on the calculated hypergeometric p-value for all
neighbor networks, 23 of them are significantly enriched in the given list of DE genes. The
constructed network includes 526 genes and 807 interactions between them (see Figure 3.7).
Here, we apply the same validation approaches explained in previous sections. The
list of pathways significantly enriched in the constructed network is shown in Table 3.19.
The Prostate cancer pathway, which is the target pathway in this condition, is reported
as significant. Most of the pathways that are ranked higher than Prostate cancer path-
way have important impacts in prostate cancer (Focal adhesion [68, 122], Estrogen signaling
pathway [26, 115], Endocytosis [39, 137], ErbB signaling pathway [42], ErbB signaling path-
way , Adherens junction [21, 103], Ras signaling pathway [6, 96, 152], Choline metabolism in
cancer [28, 37], Proteoglycans in cancer [34, 40], Rap1 signaling pathway [4]).
The common edges between the identified active network and significant KEGG path-
ways are shown in Figure 3.8. The interactions between “EGFR” and its downstream genes
such as “MAPK” and “PIK3” are very well known mechanism to be associated to prostate
cancer [30, 36, 39, 64]. Such interactions, which are shown in green in Figure 3.8, appear in
7 out of top 10 significant KEGG pathways that are ranked higher than prostate cancer.
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(a) Focal adhesion (b) Estrogen signaling pathway (c) Endocytosis
(d) ErbB signaling path-
way
(e) Adherens junction (f) Glioma (g) Ras signaling pathway
(h) Choline metabolism in
cancer
(i) Proteoglycans in cancer(j) Rap1 signaling pathway (k) Prostate cancer
Figure 3.8: The edges overlapping between the identified active network in prostate cancer and
each significantly enriched KEGG signaling pathways. The green genes represent the genes that are
associated to prostate cancer based on DisGeNET database and green edges represent the common
edges in more than 33% of the significant pathways. EGFR is a hub node in all significant pathways.
This gene and its identified interactions with downstream genes such as PIK3 and MAPK have very
strong association with prostate cancer. Such interactions occur in most of the significant pathways.
60
Prostate cancer
method rank FDR-corrected p-value
neighbor-net analysis 11 2.4e-07
NetWalker 107 1.0
HotNet 92.5 1.0
ORA 51 0.001
Table 3.20: The ranks and p-values of the target pathway (Prostate cancer pathway) in
neighbor-net analysis and three other methods. The p-values represent the significance
of the enrichment of the Prostate cancer pathway in the identified active network. The
comparisons show that neighbor-net analysis reports the target pathway more significant
and highly ranked.
We also compare the genes in the constructed network with the genes that are asso-
ciated to prostate cancer obtained from DisGeNET database. In DisGeNET, there are 148
genes that are associated to prostate cancer. There are 35 genes out of 526 in the network
constructed by the neighbor-net analysis that are associated to prostate cancer. We compare
the results of the neighbor-net analysis with the results of the NetWalker, HotNet and classi-
cal approach of selecting DE genes. The details of comparison between the proposed and the
reference methods are shown in Tables 3.20, 3.21. The p-value of observing the given num-
ber of genes known to be associated to prostate cancer in the constructed network is more
significant, as well as the target pathway is ranked higher and the corresponding p-value is
more significant in neighbor-net analysis compared to NetWalker, HotNet and classical ap-
proach. The comparisons show that the proposed method is able to report more associated
genes to prostate cancer in the constructed network compared to all reference methods. It
also identifies more related interactions to this disease based on number of overlaps with the
known Prostate cancer pathway.
3.4.4 Results of neighbor-net using interactions from BioGRID
A reasonable question might be posed regarding the degree to which the results
obtained by the proposed approach depends on the source of annotation, for instance, on
the particular database used for protein-protein interactions. In order to investigate this,
we also performed the neighbor-net analysis by using BioGRID [119] instead of HPRD, as
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Prostate cancer
method #selected
genes
#prostate can-
cer genes
% p-value
neighbor-net analysis 526 35 6% 1.8e-14
NetWalker 379 13 3% 0.003
HotNet 283 1 0.3% 0.98
Selected DE genes 2305 37 1% 0.0004
Table 3.21: The statistical analysis of the results from neighbor-net analysis and all the
methods compared in prostate cancer. The columns show: the number of genes in the iden-
tified active network reported by each method, the number of associated genes to prostate
cancer based on information obtained from DisGeNET [101], the percentages of the genes
known to be associated to prostate cancer in the total number of identified genes in each
constructed networks, and the corresponding p-values for the enrichment in each method.
The p-value of observing the given number of genes that are associated to prostate cancer in
the constructed network is highly significant in the neighbor-net analysis. The low percent-
ages is due to the fact that the total number of genes associated to prostate cancer obtained
from DisGeNET is only 148; however, the neighbor-net analysis includes higher percentage
of such genes in the constructed network compared to all three existing methods.
the protein-protein interactions resource. Same as before, we collapsed all 173 available
KEGG signaling pathways into one network with 5,052 nodes and 27,811 interactions. The
protein-protein interaction (PPI) network downloaded from BioGRID includes 2,511 nodes
and 3,440 interactions. Combing these two networks results a global graph with 10,755
nodes and 35,031 interactions. The results of all three case studies (shown in Table 3.22)
demonstrate that the proposed method is still able to find the relevant networks, which
include known mechanisms involved in the given disease in two of the three cases. We also
compared the constructed networks by neighbor-net analysis using BioGRID and HPRD and
the results are shown in Table 3.23.
3.4.5 Results of neighbor-net after removing highly connected genes
Another reasonable question is whether the method might be biased towards heavily
studied genes, like known cancer drivers, for which many more protein interactions are
known because of study and annotation bias. In order to investigate this, we also applied
the proposed approach on the same datasets, but after we excluded the genes with high
connectivity in the list of differentially expressed genes for each case study. The histogram
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Ranks and p-values of target pathways using interactions from BioGRID
disease rank of target pathway FDR-corrected p-value of target
pathway
colorectal cancer 5 2.7e-16
renal cancer 4 5.1e-06
prostate cancer - -
Number of disease-associated genes using interactions from BioGRID
disease #selected
genes
#disease
genes
% p-value
colorectal cancer 46 22 47% 3.51e-07
renal cancer 218 79 36% 4.9e-27
prostate cancer - - - -
Table 3.22: Results of neighbor-net analysis using BioGRID database as protein-protein
interactions resource. The ranks and the p-values of target pathway in three given diseases
as well as the enrichment p-value of identified genes in obtained disease-associated genes are
shown above. The neighbor-net analysis does not report any significant neighbor networks
for the prostate cancer experiments in this analysis. The significant p-values for the target
pathways and high enrichment of constructed network in known disease-associated genes
in two out of three case studies determine that the proposed method is not significantly
dependent on one specific database and is able to identify the known mechanisms involved
in the given disease by using different resources.
using HPRD using BioGRID intersection
disease number of
(nodes/edges)
number of
(nodes/edges)
number of
(nodes/edges)
colorectal cancer 144/215 46/121 39/32
renal cancer 663/1552 218/734 182/184
Table 3.23: Comparing the results of neighbor-net analysis using HPRD and BioGRID
databases. The number of nodes and edges in each constructed network, and in the inter-
section between them in colorectal cancer and renal cancer are shown.
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Figure 3.9: The distribution of the number of neighbors for each gene in the obtained network
from KEGG and HPRD databases. The number of neighbors is also the size of the neighbor
network minus one (the gene itself). The red line represents two percent of the genes, which
have more than 50 neighbors. We study the results of the proposed method by excluding
the genes connected to more than 50 genes from the analysis.
representing the degree of each gene is shown in Figure 3.9. Genes that are connected to more
than 50 genes (Top 2%) are excluded from the list of differentially expressed genes in the
analysis. The results of both evaluation approaches are included in Table 3.24. The target
pathways in colorectal cancer and renal cancer case studies are still identified significant and
highly ranked after this filtering. There was only one significant neighbor network in the
prostate cancer study hence, all the pathways except “Proteoglycans in cancer”, and ‘TGF-
beta signaling pathway” did not have any common interactions with the constructed network.
The results show that the proposed method is not simply reporting the highly studied genes
that are differentially expressed, but rather it is also able to find the mechanisms involving
the less studied genes. These putative mechanisms are still significantly enriched in truly
relevant pathways, as well as in disease genes from DisGeNET.
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Ranks and p-values of target pathways after removing highly connected genes
disease rank of target
pathway
FDR-corrected p-value of target
pathway
colorectal cancer 3 3.9e-03
renal cancer 7 1.0e-03
prostate cancer 3 1.0
Number of disease-associated genes after removing highly connected genes
disease #selected
genes
#disease
genes
% p-value
colorectal cancer 185 74 40% 1.0e-09
renal cancer 684 39 5% 7.4e-14
prostate cancer 20 4 20% 0.0002
Table 3.24: Results of neighbor-net analysis excluding the genes that are connected to more
than 50 genes. The ranks and the p-values of target pathways in three given diseases as
well as the enrichment p-values of identified genes in the obtained disease-associated genes
are shown above. The significant p-values for the target pathways and high enrichment
of constructed network in known disease-associated genes demonstrate that the proposed
method is not dependent on the highly connected genes and is able to identify the known
mechanisms involved in the given disease after excluding such genes from the analysis.
3.4.6 False positives under the null hypothesis
It is also important to investigate whether the proposed approach has the tendency
to produce false positives, i.e. construct networks claimed to be representing putative mech-
anisms that are in fact not related to the data analyzed. In order to show that this is not the
case, we applied the proposed approach on a number of randomly generated datasets. From
the graph of 11,086 genes and 62,934 interactions constructed from KEGG and HPRD, we
selected 1,000 genes to be “differentially expressed”. The proposed approach was applied to
this set of 1,000 DE genes to construct neighbor networks and calculate their significance
at the 10% level. This whole process was repeated 1,000 times. In 974 cases of these 1,000
simulations (97.4%), no neighbor network was reported as significant at this significance
level. In 24 cases (2.4%) there was only one neighbor network reported as significant. In
one case (0.1%), there were 2 significant networks and in another one case (0.1%) there were
3 networks reported as significant. These illustrate that the proposed approach produces
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substantially fewer false positives than usually accepted (10% false positives are normal for
a significance level of 10%).
3.5 Conclusion
Inferring the active network involved in the investigated disease is one of the most
important goals in system biology. Given the huge number of publicly available datasets,
disease-specific networks can be constructed by using multiple datasets from the same con-
dition to capture multiple states of the genes in the given phenotype. We take advantage
of known information about genes interactions available in multiple databases to consider
the possible disease-specific effects of genes on the genes immediately connected to them by
any kind of known interaction. The networks constructed include interactions from KEGG
and HPRD (and therefore it is reasonable to believe they are true). We also have shown
that these networks are very significantly enriched in genes known to be involved in the re-
spective diseases according to DisGeNET. Hence, we think it is reasonable to consider them
as networks describing the putative mechanisms involved in the given phenotypes. Further-
more, the results obtained from 12 datasets involving three diseases constructed networks
were shown to be able to include important genes even though they may not be differentially
expressed and therefore, they would not be found by a classical approach based on DE genes.
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CHAPTER 4: FUTURE WORK
In this thesis, we used the computed primary dis-regulation of each gene to rank and
identify the pathways that are significantly impacted in a given condition. We hypothesize
that the computed primary dis-regulation at gene level captures more information about the
genes than just their fold-change. One application of these novel computed features is in
sample classification or disease sub-typing.
Further more, we are interested in modifying the neighbor net analysis to quantify
the effect of mutations on gene expression. Changes in the gene expression have direct effect
on protein function and in turn on the progression of a disease. Quantifying these changes
are the key in understanding the disease mechanism. However, more often than not, the
causes of such changes are not easily identifiable. In many cases, genetic variants may cause
some of the observed gene expression changes.
We are proposing to introduce a method that focuses on identifying the variants
that significantly alter gene expression for an individual by integrating genetic variant data,
gene expression data, as well as a priori knowledge about gene-gene interaction networks
using neighborhood of the genes. As stated in chapter 3, the changes in a gene may not
be captured in the expression level due to the fact that gene expression data is collected at
one single time point. We are hypothesizing that the effect of variants on gene expression
is better understood if the neighborhood of each gene is considered. The integration of
different types of data helps to capture the changes in the system that are not likely to be
captured completely in any one type of data [70, 79]. This is particularly true for complex
diseases, such as cancer, which involve many phenomena that affect many levels [108, 148].
More information can be obtained if different types of data were analyzed together, thus the
integration of multiple types of data has become a very important problem to solve [130,
131, 132, 133, 134, 135, 136].
Both proposed future directions, identifying variants with significant effect on gene
expression using neighbor network and the primary dis-regulation of each gene, will be
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helpful in identifying unknown disease subtypes. Many disease have more than one subtype
due to the fact that the characteristics and progression of different diseases are the results
of the interaction between the disease and the immune system of the host [25, 117, 154].
Because of this, different patients may respond differently to the same drug. Therefore,
identifying different subtypes of a given phenotype is extremely important in selecting the
most appropriate drug [60, 72].
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A very important step in system biology is the identification of the networks that are
most impacted in the given phenotype. Such networks explain where the target genes are
affected by some other genes, and therefore describe the mechanisms involved in a biological
process. The identified networks are used to: 1) predict the disease or the responses of the
system to a specific impact, 2) find the subset of genes that interact with each other and play
an important role in the condition of interest, and 3) understand the mechanisms involved
in that condition. In this thesis, we propose an approach that takes advantage of pre-defined
pathways obtained from existing databases to identify the impact of a phenotype studied
on such pathways. Next, we introduce a method able to build a network that captures the
putative mechanisms at play in the given condition, by using datasets from multiple exper-
iments studying the same phenotype. This method takes advantage of known interactions
extracted from multiple sources such as protein-protein interactions and curated biological
pathways. Based on such prior knowledge, we overcome the drawbacks of snap-shot data by
considering the possible effects of each gene on its neighbors.
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